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ABSTRACT
Amyloids are highly ordered cross-β sheet aggregates that are associated with many diseases
such as Alzheimer‟s, type II diabetes and prion diseases. Recently a progress has been made in
structure elucidation, environmental effects and thermodynamic properties of amyloid
aggregates. However, detailed understanding of how mutation, packing polymorphism and small
organic molecules influence amyloid structure and dynamics is still lacking. Atomistic modeling
of these phenomena with molecular dynamics (MD) simulations holds a great promise to bridge
this gap. This Thesis describes the results of MD simulations, which provide insight into the
effects of mutation, packing polymorphism and molecular inhibitors on amyloid peptides
aggregation. Chapter 1 discusses the structure of amyloid peptides, diseases associated with
amyloid aggregation, mechanism of aggregation and strategies to treat amyloid diseases. Chapter
2 describes the basic principles of molecular dynamic simulation and methods of trajectory
analysis used in the Thesis. Chapter 3 presents the results of the study of several all-atom
molecular dynamics simulations with explicit solvent, starting from the crystalline fragments of
two to ten monomers each. Three different hexapeptides and their analogs produced with single
glycine replacement were investigated to study the structural stability, aggregation behavior and
thermodynamics of the amyloid oligomers. Chapter 4 presents multiple molecular dynamics
(MD) simulation of a pair polymorphic form of five short segments of amyloid peptide. Chapter
5 describes MD study of single-layer oligomers of the full-length insulin with a goal to identify
the structural elements that are important for insulin amyloid stability, and to suggest single
glycine mutants that may improve formulation. Chapter 6 presents the investigation of the
mechanism of the interaction of polyphenols molecules with the protofibrils formed by an
amyloidogenic hexapeptide fragment (VQIVYK) of Tau peptide by molecular dynamics
ii

simulations in explicit solvent. We analyzed the trajectories of the large (7×4) aggregate with
and without the polyphenols.
Our MD simulations for both the short and full length amyloids revealed adding strands
enhances the internal stability of wildtype aggregates. The degree of structural similarity
between the oligomers in simulation and the fibril models constructed based on experimental
data may explain why adding oligomers shortens the experimentally observed nucleation lag
phase of amyloid aggregation. The MM-PBSA free energy calculation revealed nonpolar
components of the free energy is more favorable while electrostatic solvation is unfavorable for
the sheet to sheet interaction. This explains the acceleration of aggregation by adding nonpolar
co-solvents (methanol, triﬂuoroethanol, and hexaﬂuoroisopropanol). Free energy decomposition
shows residues situated at the interface were found to make favorable contribution to the peptide
-peptide association.
The results from the simulations might provide both the valuable insight for amyloid aggregation
as well as assist in inhibitor design efforts. First, the simulation of the single glycine mutants at
the steric zipper of the short segments of various pathological peptides indicates the intersheet
steric zipper is important for amyloid stability. Mutation of the side chains at the dry steric zipper
disrupts the sheet to sheet packing, making the aggregation unstable. Thus, designing new
peptidomimetic inhibitors able to prevent the fibril formation based on the steric zipper motif of
the oligomers, similar to the ones examined in this study may become a viable therapeutic
strategy. The various steric zipper microcrystal structures of short amyloid segments could be
used as a template to design aggregation inhibitor that can block growth of the aggregates.
Modification of the steric zipper structure (structure based design) with a single amino acid
changes, shuffling the sequences, N- methylation of peptide amide bonds to suppress hydrogen
iii

bonding ability of NH groups or replacement with D amino acid sequence that interact with the
parent steric zipper could be used in computational search for the new inhibitors.
Second, the polyphenols were found to interact with performed oligomer through hydrogen
bonding and induce conformational change creating an altered aggregate. The conformational
change disrupts the intermolecular amyloid contact remodeling the amyloid aggregate. The
recently reported microcrystal structure of short segments of amyloid peptides with small organic
molecules could serve as a pharamcophore for virtual screening of aggregation inhibitor using
combined docking and MD simulation with possible enhancement of lead enrichment.
Finally, our MD simulation of short segments of amyloids with steric zipper
polymorphism showed the stability depends on both sequence and packing arrangements. The
hydrophilic polar GNNQQNY and NNQNTF with interface containing large polar and/or
aromatic side chains (Q/N) are more stable than steric zipper interfaces made of small or
hydrophobic residues (SSTNVG, VQIVYK, and MVGGVV). The larger sheet to sheet interface
of the dry steric zipper through polar Q/N rich side chains was found to holds the sheets together
better than non Q/N rich short amyloid segments. The packing polymorphism could influence
the structure based design of aggregation inhibitor and a combination of different aggregation
inhibitors might be required to bind to various morphologic forms of the amyloid peptides.
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CHAPTER 1
1.1

INTRODUCTION

Protein structure and function

Proteins are the major macromolecular component of the cell that are synthesized in the
ribosomes and are responsible for most of the cell‟s biological activity. Proteins play a variety of
roles in the cell, including structural (cytoskeleton), mechanical (muscle), biochemical
(enzymes), and cell signaling (hormones). Proteins consist of a linear polycondensate of amino
acids linked together by peptide bonds in a specific sequence. This specific sequence is
responsible for the protein‟s structure and function. A peptide bond formed between two amino
acids is the primary element of peptide and protein structure. Protein structure has four main
organizational levels: primary, secondary, tertiary and quaternary.1
Primary structure of proteins and peptides is defined by the linear sequence of amino
acids. There are 20 naturally occurring amino acids, which differ in size, shape, charge,
hydrogen bonding ability, hydrophilicity, and chemical reactivity. The sequence of the amino
acid in the primary structure is unique to each protein. A one-letter or

a three-letter

abbreviations are used to identify sequence of amino acids in a protein.1 The amino acids
chemically combine via amide bonds to from polypeptide chains. The biosynthesis of proteins
starts at the N terminus and ends at the C terminus, which carry positive and negative charges
respectively at the physiological pH. The sequence of amino acids in the primary structure is
unique to each protein and dictates its overall function. Depending on the number and nature of
substitution, changes in the primary sequence may or may not change the overall structure.1 If
the change is due to substitution between closely related residues (such as tyrosine and
phenylalanine) the three dimensional structure and its function is generally conserved. However,
1

changes in primary sequence which does not conserve the three dimensional structure leads to
protein misfolding which is associated with protein misfolding diseases.2
Secondary structure is a localized spatial arrangement of amino acids. It is the first step in
the folding of proteins and polypeptides. There are three types of secondary structures: helices,
beta sheet and turns.
A helix is characterized by the number of residues per turn, the number of atoms making
the cycle formed by the hydrogen bond and the repeat distance. The most common helix is the helix with a 3.6 residues per turn where hydrogen bonds are formed between C=O of residue n
and N-H of residue n+4 (Figure 1-1). The other less common helices are the 310-helix and πhelix. The 310-helix has 3 residues per turn forming a hydrogen bond between C=O of residue n
and N-H n+3. The π-helix is a more loosely coiled helix between C=O of residue n and N-H
n+5.3 The amino acids proline, hydroxyl proline and glycine break -helices. Other amino acids
such as glutamine, methionine, leucine tend to stabilizes helical structures.4
The β-sheets are the other most common structural element in protein. The β-sheet,
unlike the -helix, can be built from a combination of several regions of the polypeptide chain.
The β-sheets are made up of two or more strands laterally pack together such that hydrogen
bonds can form between C=O groups of one β–strands and N-H groups on an adjacent β –strands
and vice versa. β –strands can arrange next to each other to form sheets. The directionality of
adjacent β –strands leads to the formation of “parallel”, “antiparallel” and “mixed” β-sheets.1
Among amino acids valine, isoleucine and phenylalanine have been found to stabilize β-sheets.

2

Proline which cannot participate in the formation of hydrogen bonds between strands destabilizes
β-sheets.
Most proteins structures based on combinations of -helices and β-sheets are connected
by turns or loops of various lengths and irregular shapes. Turns have the universal role of
enabling the polypeptide backbone to change direction and are important elements that allow and
drive protein compaction. Analysis of the amino acid composition in turns reveals that bulky or
branched side chains occur rarely while residues with Gly, Asp, Asn, Ser, Cys and Pro with
small side chains are observed predominantly in turns.3,4
The tertiary structure represents the three dimensionally folded polypeptide chain. The
secondary structure is stabilized through hydrogen bonding while the tertiary structure stability is
mainly due to hydrophobic/hydrophilic interactions as well as salt and disulfide bridges. The
nonpolar residues tend to collect in the center of the protein while the hydrophilic residues are in
the surface of the protein. The size and the shape of a protein is determined by the length of the
amino acids and by how the secondary structure is arranged inside the protein.1
Many proteins are made up of more than one polypeptide chain. The structure formed
upon the interaction between single tertiary structures of more than one polypeptide chain is
called quaternary structure. The interactions responsible for the quaternary structure are the same
as in the tertiary structures. The subunits in the quaternary structure could be based on either
identical or different subunits. Quaternary structure of proteins allows greater regulation of
transport function and enzyme activity.3,1 Following their synthesis protein molecules must fold
into native conformation to perform their biological functions. However under some conditions
3

proteins fail to fold correctly leading to protein aggregation both in vivo and in vitro. The
aggregated proteins lack the biological activity of the native protein and are associated with
pathological conditions5 and are a major problem in the manufacturing of proteins.6

1.2

Protein aggregation

The ability of proteins to fold from the linear sequence of amino acid forming a
functional conformation is one of the most important biological processes. Certain conditions
(such as environmental conditions7, and mutation8) initiate misfolding of protein. Protein
misfolding leads to a loss of the function carried out by that protein. The correct folding of a
protein involves temporary interactions with helper protein or molecular chaperones and is
governed by evolutionary pressures that adjust the folding rates according to physiological
requirements. Incorrect folding of a protein results in protein aggregation. Protein aggregates are
insoluble molecular self-assembly that have lose of their native conformation and function. It has
been shown that the protein aggregation can be influenced by a number of variables that
includes: a) environmental factors which include concentration of protein, type of solvent, salt
content, metal ions, pH of medium, temperature and pressure and b) structural factors involving
hydrophobicity, polarity and β-sheet secondary structure content.9 Protein aggregation that is
commonly found in biopharmaceutical industries is unwanted in protein drug production.6 The
aggregates are major concern in the manufacturing process such as purification, freeze drying
and storage. Protein aggregation is also associated with a number of human diseases and is
gaining an increasing role in human health.9 The mechanism explaining how amyloidoses cause
cell death in neurodegenerative diseases still evades our knowledge. Plaques of aggregated
4

amyloid fibrils, originally suggested as the cause of the disease are no longer considered to be
the pathogenic factor. Instead, the small soluble oligomers

10,11

formed at the beginning of the

aggregation process are now believed to be the main cytotoxic entities. Amyloid forming
proteins have been demonstrated to form pore-like(channel) structures in artificial as well as
biological membranes.12 These ion channel structures have been proposed as the reason for cell
pathophysiology and degeneration in amyloid diseases.13

1.3

Amyloid aggregation and occurrence of amyloid disease

Amyloid and amyloid like fibrils are elongated, insoluble protein aggregates deposited in
vivo in amyloid disease or formed in vitro from soluble proteins. Many amyloid proteins are now
known (Table 1-1) and although they vary in primary sequence, origin and significance in
normal versus aberrant physiology, they all share the property of forming water-insoluble stable
aggregates with β-sheet structures. In recent years, amyloid proteins have been found throughout
the human body, in a variety of different species, and playing a key functional role in some
cases.14 These discoveries have challenged the previous implication that amyloids occur through
defective protein folding and cause disease, suggesting instead that amyloids may comprise
evolutionally conserved folds that perhaps have important, as yet unidentified, roles in normal
cellular physiology.15 Over 30 human diseases are now associated with amyloidogenesis (Table
1-1), the formation of aggregated β-sheet structures that appear as water-insoluble deposits of
“amyloid” fibrils. Amyloidosis can be classified very broadly into either localized or systemic
amyloidosis, depending on the location of the amyloid fibres and the genetic (hereditary) or
acquired nature of the precursor protein.
5

1.4

Structure of amyloid fibrils

Amyloid fibrils are linear unbranched protein aggregates associated with several
degenerative diseases as well as denatured globular proteins, bacterial inclusion bodies and
several normal cellular functions.16,17 Fibrils appear to arise from the spontaneous unfolding of
the proteins, the exposure of fibril-forcing segments and subsequent self-assembly.18 These
fibrils share enriched β-structure reflected in a cross-β diffraction pattern and Congo red
birefringence.19,20 The atomic-resolution structures of amyloid-forming peptides have been
recently determined using X-ray diffraction, electron microscopy, atomic force microscopy, solid
state NMR (ssNMR), and computational methods.21,22,23 It is challenging to investigate the
structure and dynamics of amyloid fibrils at the residue and atomic resolution because of their
high molecular weight and heterogeneous properties. The one-dimensional nature of the order in
the fibrils makes them poor candidates for three-dimensional crystallization. To date, the only
representative crystal structures are of amyloidogenic peptides that are short enough to pack in a
three-dimensional lattice.24 These structures indicate that the most basic cross-β structure is in
fact a one-dimensional crystal with single translational and rotational symmetry elements. Being
neither 2D nor 3D-crystalline nor soluble, protein fibrils are difficult to investigate by X-ray
diffraction or solution NMR methods, and ssNMR is the method of choice for the
characterization of their structure and dynamics.25
As reported by Eisenberg et al.,26 almost all complex proteins, even though not
structurally similar, have short segments that if exposed to an appropriate environment (and
sufficiently flexible) are capable of triggering amyloid formation. The modern biophysical
description of amyloid is unbranched protein fiber whose repeating substructure consists of β
6

strands that run perpendicular to the fiber axis (Figure 1-2), forming a cross-β sheet of indefinite
length.2 Thus, amyloids are composed of an ordered arrangement of many (usually thousands)
copies of a peptide or protein. They are easily identified using electron microscopy (EM) as long
filaments with diameters of 6–12 nm.27 The repeating cross-β sheet motif gives rise to
characteristic X-ray fiber diffraction pattern with meridional reflections at ~4.7 Ǻ corresponding
to the inter-β strand H-bonding and equatorial reflections at 6–11 Å corresponding to the
distance between stacked β sheets.28,29
Eisenberg et al. were able to grow three-dimensional microcrystals16 and determine
atomic resolution structures, using short fibril-forming peptide segments of amyloid proteins.
These structures provided the atomic details of the cross-β spine architecture: a steric zipper
made of two β-sheets (8.5 Å apart in this case) mating at a dry, complementary interface of
interdigitated side-chains. Each sheet is built by hydrogen bonding (H-bonding) of identical
segments along the fibril direction, separated by 4.9 Å.22,30 While H-bonds hold each sheet
together, van der Waals interactions bind the two sheets into the zipper spine. In contrast to the
microcrystals, the fibrils show an interstrand twist angle that contributes to their stability,
providing self-assembling and self-healing properties31,32 Twist reflects the fact that successive
protein chains in a β-sheet are not stacked exactly above one another but with a small angular
offset.32 This twisting optimizes the H-bonds, side-chain stacking, and electrostatic
interactions.33
Even though amyloids were originally primarily associated with neurodegenerative
diseases, in recent years, a steadily growing number of specific amyloids have been discovered
that demonstrate biologically functional properties. Some of the amyloids were found to cause
7

amyloidosis in mammals by infection (termed Prions, from “infectious proteins”), others are not
infectious and may be accumulated for internal reasons. While pathological for mammals, some
Prions are functional in yeast and fungi (such as HET-s). Atomistic amyloid models have been
recently classified into three types (see Figure 1-3). Type 1, characteristic of disease amyloids, is
formed by lateral stacking of identical β-arches (strand-loop-strand motif). Type 2 is also
pathological; it consists of superpleated β-arches with more than two strands. The functional
amyloids (FA), in contrast, were found to belong to Type 3 that is called β-solenoids. The βsolenoids are built of repeated coils of two or more β-arches long with non-identical but related
sequence alternates along the fibril34

1.5

Nucleation and template assisted self assembly of amyloid peptides

Molecular self assembly governed by noncovalent interactions is common in nature. The
spontaneous organization of peptides or proteins is of biomedical significant as they are
associated with various amyloid diseases (Table 1-1). Amyloid fibril formation appears to be a
multistep process during which a number of intermediate aggregates are formed. The
aggregation starts with the coalescence of peptide monomers to form small oligomeric
aggregates such as dimers, trimers, etc. These small oligomers then grow further in size and
complexity evolving into protofibrils and then mature amyloid fibrils. The full mechanism of
amyloid aggregation is still unclear. The formation of amyloid can be considered to involve at
least three steps (Figure 1-4) and are generally referred to as lag phase, growth phase (or
elongation) phase and an equilibration phase. The lag phase represents the early stage of the
amyloid fibril formation, prior to any detection of fibrils. During the fibril growth phase, the
8

initially soluble fibrils may become insoluble and precipitate as they exceed certain size and
solubility limit. The equilibrium phase (or steady state phase) refers to a situation where the
system, consisting of for example fibrils and monomers, appears to be in equilibrium. Although
the first step is under kinetic control, fibril growth is under thermodynamic control and can be
evaluated quantitatively in terms of equilibrium properties such as association constants.
Among amyloid formation and other nucleated processes a shared feature is that the lag
phase can be accelerated on addition of aggregate which is referred to seeding.35 Seeding
involves the addition of a preformed fibrils to a monomer solution thus increasing the rate of
conversion to amyloid fibrils.36 Addition of seeds decreases the lag phase by eliminating the
slow nucleation phase. Seed can be homogenous (same peptide) or heterogeneous (related or
unrelated peptide) as long as it can provide its growth face as a template for the polymerization
of the complement monomers. Recent studies of amyloid growth indicate that, in addition to the
self-interactions mediating pathogenic self association, cross-amyloid interactions (also referred
as cross seeding) may play a critical role in amyloid diseases. Examples of such interactions
include the Aβ–tau, Aβ-amylin, tau–-synuclein, and Aβ–transthyretin interaction.37, 38, 39, 40,41

1.6

Designing of aggregation inhibitors

In the case of protein aggregation disease the development of therapeutics agent is
focused on interfering with aggregation pathway or increase degradation of misfolded
aggregates.42,43 At least five different targets have been proposed to intervene against
aggregation in amyloid disease (Figure 1-5) which includes: A) decrease the expression of the
protein associated with the misfolding and aggregation; B) native protein stabilization; C)
9

inhibition aggregation and reversal of protein conformational changes; D) increase the clearance
of the misfolded protein; and E) prevent tissue degeneration induced by misfolded aggregates.
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Table 1.1 Examples of the most common human protein aggregation diseases and the protein
associated with the diseases.44
Pathological condition

Protein associated with the diseases

Alzheimer‟s disease
Spongiform encephalopathies
Primary systemic amyloidosis
Secondary systemic amyloidosis
Fronto-temporal dementias
Senile systemic amyloidosis
Familial amyloid polyneuropathy I
Hereditary cerebral amyloid angiopathy
Haemodialysis-related amyloidosis
Familial amyloid polyneuropathy III
Atrial amyloidosis
Hereditary non-neuropathic systemic
amyloidosis
Hereditary renal amyloidosis
Injection localised amyloidosis
Huntington's disease
Spinocerebellar ataxias
Medullary carcinoma of the thyroid
Parkinson's disease
Type II diabetes
Glaucoma

Aβ peptides (plaques); tau protein (tangles)
Prion proteins (full length or fragments)
Immunoglobulin light chains (full length or fragments)
Serum amyloid A (full length or 76-residue fragment)
Tau (wild type or mutant)
Transthyretin (full length or fragments)
Transthyretin (more than 45 mutants)
Cystatin C (minus a 10 residue fragment)
β2-Microglobulin
Apolipoprotein A1 (fragments)
Atrial natriuretic factor
Lysozyme (mutants)
Fibrinogen
Insulin
Huntingtin (intact or poly(Q) rich fragments)
Ataxins (intact or poly(Q) rich fragments)
Calcitonin
-Synuclein (aa 1-100)
Amylin (aa 1-37)
Aβ peptides

11

A

B
Figure 1.1Alpha (A) and beta sheet (B) secondary structure of amyloid peptides. A) alpha-helix
structure of A1-42 (Pdb code 1IYT), with helix I (residue 8-25) connected to helix II (residues
28-38) by a turn (residues 26-27). B) β-sheets structure of a short peptide segment of amyloid
peptides. The GNNQQNY segment from yeast prion amyloid with parallel (left panel pdb code
1YJP) and VQIVYK segment from human tau amyloid protein (right panel pdb code 2ON9)
with antiparallel conformation. Hydrogen and carbon atoms are colored gray, nitrogen blue and
oxygen red. The hydrogen bonds are represented with green line. Image created with chimera.45
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Figure 1-2 Structure of amyloid peptides (Adopted from 2) (A) Amyloid fibrils are composed of
long filaments that are visible in negatively stained transmission electron micrographs; (B)
Ribbon diagram of the cross-β sheets in a fibril, with the backbone hydrogen bonds represented
by dashed lines; (C) the fiber diffraction pattern with a meridional reflection at 4.7 Å (black
dashed box) and an equatorial reflection at 6–11 Å (white dashed box), that arise from the βstrand and β-sheet spacing respectively. Adopted from Ref 2,24
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Figure 1-3 Three types of cross beta models of amyloid protofibrils; top: axial views of the
repetitive structural units (rectangles represent β strands); bottom: lateral views of protofibrils
formed by stacking of these repetitive units. Orange circles in the insulin model show Cys
residues forming disulfide bonds. Beneath, schematic diagram of a β arcade, considered to be
structural motif common to all 3 types of models. One β arch is colored in blue, with depth
cuing; arrows indicate β strands; dotted lines show H bonds. Adopted from Ref. 32
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Equilibrium phase
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Fibrillation time

Fibril growth

A

Add seed

Fibrillation time

B
Figure 1-4 Amyloid aggregation growth curve (A) and effect of addition of seeds on the lag
phase (B) Adopted from Ref. 35
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Figure 1-5 Mechanism of nucleation dependent amyloid fibril formation and cross seeding
Adopted from Ref. 46,47
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Figure 1-6 Amyloid aggregation and therapeutic intervention in amyloid diseases. The
conversion of normally soluble peptides and proteins into insoluble aggregates illustrated in a
schematic manner. The stages in the aggregation process where therapeutic intervention may be
able to prevent or reverse aggregation are indicated. Therapeutic strategies include (A)
stabilizing the native state; (B) inhibiting enzymes that process proteins into peptides with a
propensity to aggregate; (C) altering protein synthesis; (D) stimulating clearance of misfolded
proteins, for example, by boosting their proteasomal degradation; (E) perturbing fibril assembly;
(F) neutralizing or preventing accumulation of fibril precursors. Adopted from Ref. 9, 43
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CHAPTER 2

MOLECULAR DYNAMIC SIMULATION AND
TRAJECTORY ANALYSIS
2.1

Bimolecular Simulations

Molecular simulation is a way to visualize a system by generating successive
configurations of the system. While experimental techniques such as x-ray crystallography can
generate a snapshot of a protein (or other macromolecule), the positions of mobile elements, such
as flexible loops, may remain unclear. It is possible to visualize these mobile elements with
simulations. Additionally, x-ray crystallography and NMR methods are often employed under
non-physiological conditions (temperature, pressure, pH, solvent, etc.), which can affect their
results in unpredictable ways. Many biologically important process involves a change in the
three dimensional structures of bio-molecules such as protein, RNA and DNA.48 Protein folding,
protein aggregation, enzymatic catalysis, signal transduction and other biological process involve
conversion of proteins structures.48 Bimolecular simulations can provide information to the
molecular modeler about how a biological system behaves over a certain time period, under
physiological conditions

49

providing continuous trajectories that can help in connecting static

experimental structures. Therefore computer simulations are used to complement and extend
experiment.50
There are two main types of simulation methods: Molecular Dynamics (MD) and Monte
Carlo (MC) simulations. In MD, the configurations are produced by integrating Newton‟s laws
of motion, resulting in a trajectory that specifies how the system behaves with time. The forces
on the atoms are used with their current positions and velocities to predict new positions and
velocities for the next time step. Over a given time period, a “trajectory” is generated that
24

describes how the system being studied changes over time. Time averages for thermodynamic
properties such as internal energy, heat capacity, pressure, and temperature can be calculated.
2.2

Molecular dynamic simulation

Molecular Dynamics (MD) simulation is a computer simulation which uses molecular
mechanics to describe the time evolution of a set of interacting atoms by integrating their
equations of motion.51, 52 MD simulation follows the laws of classical mechanics (Newton's law)
for system constituted by N atoms, each atom at position ri is treated as a point with a mass mi
and a fixed charge qi: the force Fi acting upon each atoms is determined by:
Fi = -U(R),

(1)

Where, U(R) is the potential energy of the system as a function of the atoms positions. It is a sum
of energy contributed from oscillations about the equilibrium bond length (Ubond), oscillations of
3 atoms about an equilibrium bond angle (Uangle), torsional rotation of 4 atoms about a central
bond (Udihedral) and non-bonded energy terms which consists of electrostatics and Lenard-Jones
(Unonbond).50

U(R)= Ubond + Uangle + Udihedral + Unonbond

(2)

Once the potential energy of the system is obtained using equation 2, the force on each atom can
be obtained by solving equation 1. The calculated force determines the acceleration of the atoms,
knowing the positions and velocities at time t one can calculate the positions and velocities of the
atoms at time (t+t):
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(3)
(4)
The continuation of the steps above is a trajectory of the position and velocity of the atoms
which varies with time.50 Thus the MD simulation provides time dependent motions of the
individual atoms in the system.

2.2.1

Potential energy function

MD simulations are based on knowledge of the potential energy surface which is
represented by an empirical function called force fields. The force field is a collection of
equations and associated constants designed to reproduce molecular geometry and selected
properties of tested structures. The force fields are parameterized to approximately reproduce
various experimental results from spectroscopy, calorimetry and/or quantum mechanical
studies.50 The chief advantages of force fields are the incredible reduction in computational
requirements. The disadvantage of force fields is they ignore electronic effects and cannot be
used to describe molecular properties that depend upon electron distribution, such as chemical
reactions. The functional form for typical force field in AMBER package is given by the
following equation 53:
U bonded =

(5)

U non bonded =

(6)
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where U

bonded

is the contribution to the total energy from bonded interactions and U

non bonded

is

the contribution from non bonded interactions. The total energy is then: U total = U bonded + U nonbonded.

The first term in Eq. 5 is a sum over all bonded pairs of atoms and describes the stretching

of bonds; b is the inter-atom distance (i.e., bond length); and Kb and b0 are parameters describing
the stiffness and the equilibrium length of the bond, respectively. The term has the same
quadratic form as that of Hooke‟s law for the potential energy of a spring. The second term
involves triplets of atoms, e.g., A, B, and C, where A is bonded to B and B is bonded to C, and
describes the bending of angles. θ is the angle formed by the two bond vectors, Kθ and θ0 are the
parameters describing the stiffness and equilibrium geometry of the angle, and, similar to the
term for bond stretching, the term is quadratic. The third and final term in Eq. 5 is a sum over
quadruplets of atoms A, B, C, and D, where A is bonded to B, B to C, and C to D, and describes
the energetic associated with rotation of the dihedral angle defined by those four atoms. Because
such rotation is necessarily periodic in nature, a cosine function is used. χ is the value of the
dihedral, Kχ is the energetic parameter that determines barrier heights, n is the periodicity or
multiplicity, and σ is the phase. It should be noted that the bonded terms are also referred to as
internal or intra-molecular interactions.49
The non-bonded interactions between atoms are defined as occurring either between
atoms in separate molecules or between atoms separated by three or more bonds in the same
molecule. Equation 6 is composed of two parts. The first, known as the Lennard-Jones (LJ)
equation, is the portion in square brackets along with the prefactor εij , and models attractive
dispersion and repulsive Pauli exclusion interactions and is commonly referred to as the van der
Waals term. As two atoms are brought together from infinite separation, the negative term in the
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brackets, which goes as the inverse of the inter-atomic separation rij to the sixth power,
dominates the interaction and the atoms feel an increasing attraction with decreasing distance as
the energy becomes progressively more negative. This part of the LJ equation models dispersion,
and its (1/r )6 form derives from the interaction energy of an instantaneous dipole with an
induced dipole, according to the definition of London‟s dispersion. As the atoms get
progressively closer, an energy minimum is reached and, at closer distances, the (1/r)12 term,
which is positive, starts to dominate and leads to increasing energy and, hence, repulsion. Its
form was originally chosen based on its computational expedience because it is simply the
square of (1/r)6. Nonetheless, it serves as an adequate representation of the very steep repulsive
energy wall that arises from Pauli exclusion as two atoms get closer than the sum of their van der
Waals radii. The prefactor, εij, is a parameter based on the types of the two interacting atoms i
and j. As its value increases, the interaction minimum becomes deeper and the repulsive wall
steeper. Rmin,ij is a parameter that also depends on the types of the two interacting atoms and
defines the distance at which the LJ energy is a minimum. The second part of Eq. 6 is Coulomb‟s
law and is used to model the electrostatic interaction between non-bonded pairs of atoms. As
with the LJ equation, ri j is the inter-atomic distance, while qi and q j are the parameters that
describe the effective charges on atoms i and j. It is important to note that the effective charge
parameters are not simply unit charges located on formally charged atoms. Rather they are
partial atomic charges with non-integer values that are selected to represent the overall charge
distribution of a molecule. Naturally, the sum of the partial charges in a molecule must equal the
molecule‟s net formal charge. In addition, in the case of metal ions, the charge is typically
assigned the formal charge (e.g., +1 for the sodium ion).49 MD packages available for
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commercial or academic use frequently incorporate their own force field which has already been
parameterized by the developers. Some commonly used dynamics packages that include their
own force fields are AMBER, CHARMM, and GROMACS.54,55,56 There are a variety of
integration methods currently employed by dynamics software packages, including the Verlet
algorithm, 57 the „leapfrog‟ algorithm,58 the velocity Verlet method,59 and Beeman‟s algorithm.59
The most widely employed integration methods today are Verlet and velocity Verlet methods.
The Amber package employed in our MD studies uses the velocity Verlet integration method by
default.54

2.2.2

System setting in MD simulation

Setting up and running a molecular dynamics simulation is a complicated process which
requires many considerations, such as the initial configuration of the system being studied,
choice of force field and dynamics integration method, time length of the simulation and time
steps, type of ensemble and energy calculations, boundary conditions, and solvation. Each
consideration can influence the outcome of the simulation as well as the computational expense
and time requirements. The initial configuration of the system is usually obtained from
experimental data, theoretical models, or a combination of both. For example, for a protein
simulation, the structure of the protein may have been obtained from x-ray crystallography,
NMR, or homology modeling. Atom types for the force field being used must be defined and
parameters developed if necessary. The systems are frequently minimized prior to running
dynamics to eliminate high energy interactions such as steric clash.60
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Once the initial configuration of the system has been defined and the force field and integration
method (software package) selected, decisions must be made as to the length of time and the
time steps that will be required for the simulation. The length of time will be determined by the
nature of the system being studied, the process being studied, and the computational resources
available to the modeler.. The calculation time steps is another key consideration and it depend
on the integration method being used, the system studied, and the computational resources
available.60 The smaller the time step chosen, the more computational expensive will be the
simulation. A standard recommendation is that the time step chosen should be one-tenth the time
of the shortest motion being studied. In bio-molecular systems this is usually the C-H bond
vibration which occurs on a 10 fs time scale, thus 1fs time steps would typically be chosen. If CH bonds are held constrained during the simulation using a method known as the SHAKE
algorithm, then this time step can be doubled to 2 fs.

61

The next consideration is the type of

ensemble to be studied and the types of energy calculations that will be used. Molecular
dynamics are traditionally performed using the NVE or micro-canonical ensemble, which holds
constant the number of particles (N), the volume (V) and the energy (E). When studying biomolecular systems, it is more practical to use the NTP, or isothermal-isobaric ensemble, which
holds constant the number of particles (N), the temperature (T), and the pressure (P). This
simulates physiological conditions more closely than the other types of ensembles.

2.2.3

Treatment of long range columbic force

The most time consuming part of a molecular dynamics simulation is the calculation of
long range interactions and there are a variety of methods for handling this. The use of distance
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cutoffs for energy calculations is one popular way to address this problem. Cutoffs present a
problem with certain types of long-range interactions, such as charge-charge interactions which
can still significantly contribute to the energy of the system beyond the standard cutoffs used in
most dynamics simulations. Special methods have been developed to address this problem,
including the Ewald summation. The version of Ewald summation method known as ParticleMesh Ewald (PME) is employed in the Amber simulations package.54

2.2.4

Boundary condition and solvent models

Finally, boundary conditions and solvation methods must be decided upon. Because
interactions at the boundaries of the system being studied (i.e. vacuum, wall, etc.) can influence
the energy calculations, the boundaries must be defined or taken into account in some manner.
For bio-molecular simulations, the most common way to do this is to employ periodic boundary
conditions. Periodic boundaries involve placing the system in a cell, typically a cubic box or
other geometric shape, and then surrounding the cell with mirror cells containing replicas of the
system. The interactions energies can be calculated across cell boundaries overcoming the
boundary effect and enabling the simulation of a much larger system. If a particle leaves one side
of the cell, it subsequently enters from the other side; keeping the number of particles in the
system constant. The cell size chosen must be large enough so that the actual bio-molecule being
studied does not “see” itself and affect its own energy calculations. Usually, it is desirable only
for solvent molecules to cross the periodic boundary.54
There are currently three different ways to take into account solvation: the first one
involves simulating the system in vacuum using only a distance dependent dielectric screening
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term in the force field to simulate the solvent screening effects on electrostatic charge
calculations. This method is the least rigorous, and is the fastest in terms of computational
expense; however it is also the least reliable and should be reserved only for simulations where
solvent effects is not expected to play a key role. The second method is known as implicit
solvation, or continuum solvation.60 This method uses special energy terms in the force field to
represent the solvent as a continuous medium. The two commonly used algorithms to
approximate the solvent electrostatic effects are the Poisson-Boltzmann equation, and the
Generalized Born model, which is a linear approximation of the Poisson-Boltzmann equation
which is computationally less expensive. Both of these equations are often combined with a
hydrophobic solvent accessible surface area (SA) term. Implicit solvation models still have
limitations. Entropic effects are not accounted for in these models, which can be a major factor in
loop movements, ligand binding, and protein folding. The effect of solvent viscosity on the
motion of solutes is also not accounted for when using implicit models, although in some cases
this can be desirable. Finally, although H-bonding can be generally accounted for with implicit
solvation algorithms, the directionality of H-bonds cannot. The third solvation method is the
explicit solvation. In this method the solvent molecules are explicitly treated by surrounding the
solute or bio molecule by solvent molecules. This method is the most accurate but is also
computationally the most expensive as all energy calculations must now include the many
solvent molecules. For bio-molecular simulations, there are several water models that have been
designed for use, the most commonly used is the TIP3P water model, a 3-site model where the
water is represented by a molecule with 3 interaction sites and a rigid shape

32

62

4, 5 and 6 site

models have been developed but they increase the computational expense of the simulation and
are rarely used except for simulations modeling water dynamics.49
Once the molecular dynamics methods have been determined and the system has been set
up, the simulation can be run. A typical dynamics simulation of a bio-molecular system under
explicit solvation is a multi-step process. An initial solvent minimization is required, where the
solvent is minimized while the solute is held under constraint. This is followed by a solvent
dynamics step, where the solvent (and any counter ions added to balance the solute charge) are
allowed to equilibrate. The next step would be allowing the entire system to minimize while
slowly loosening the constraints on the solute, or bio-molecule. This is followed by the dynamics
simulation itself which occurs in two phases, an equilibrium phase and a production phase. The
equilibrium phase brings the system to equilibrium from the starting configuration. Equilibration
is reached when the calculated average temperature, pressure, and energies have stabilized.
Finally, the production phase of the simulation can begin, where the system is allowed to fully
evolve for the desired time period. Typically only data obtained from the production phase is
used to calculate the desired properties.49

2.3

Simulation protocol

Molecular dynamics (MD) simulations of various size short segment and full length
amyloid peptides and their corresponding mutant as well as were performed using the MD
simulation given below.
The molecular dynamic (MD) simulation in this thesis were performed using
AMBER1163 package with an all atom amber99SB force field and explicit TIP3P water models.
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Each of the amyloid peptides, the corresponding mutants and amyloid polyphenol complexes
were solvated by explicit water molecules that extends 10 Å from any edge of the octahedral box
to the protein atoms. Counterions were added to the box by randomly replacing water molecules
to neutralize the system. Energy of each system was initially minimized by using conjugate
gradient method to remove bad contacts with the peptide atoms first constrained, and then
relaxed without position constrains. The system was then subjected to 50 ps of heating procedure
while constraining the backbone atoms of the protein to allow relaxation of water and ions,
followed by 500 ps equilibration run without position constraints on the peptides. Constant
pressure (1 atm) and temperature (300 K) on the system was maintained by isotropic Langevin
barostat and a Langevin thermostat. Electrostatic interactions were calculated by using the
particle mesh Ewald (PME) method. The cutoff radius for the Lennard-Jones interactions was set
to 12 Å. The SHAKE algorithm
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was used for bond constraints and the time step was 2 fs for

all simulations. Each system was simulated for 20 ns and the trajectories were saved at 4.0 ps
intervals for further analysis. The VMD (Visual Molecular Dynamics) program was used for the
visualization of the trajectories.65 The MM-PBSA single trajectory approach implemented as
script (MMPBSA.py) in AMBER11, was used to calculate the binding energy. The length of the
production simulation for the systems in chapter 3 was 10 ns. The simulation temperature was set
at 330 K for the amyloid peptide models in chapter 5. The temperature 330 K was selected as a
compromise so that amyloid fibrils are still experimentally stable66,67,68 but molecular system
evolves more quickly in the limited simulation time and possible kinetic traps are avoided. The
force parameter for curcumin, exifone and myricetin in chapter 6 was generated by GAFF utility
69

in AMBER11 suite. Geometry optimization and partial charges were obtained using
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Gaussian03 70. After geometry optimization at HF/6-31G* level, the partial charges were derived
by fitting to the gas-phase electrostatic potential at the same theory level using the restrained
electrostatic potential (RESP) method.

2.4

Analysis of MD trajectories

The trajectory analysis of the simulations was performed using the analysis tools
available in VMD, and in ptraj module of AMBER software. MD simulations produce
trajectories for the atomic positions and velocities. These quantities are saved at regular intervals.
Usually positional information is mainly used the analysis of MD simulations. Several analyses
are done once the simulation has been completed to extract structural and energetic information
from the production run. The goal of the trajectory analysis is to gain structural and dynamic
insights and relating structure to function. The ptraj program in AMBER soft is capable of
analyzing and processing trajectory created from MD simulations.54 The most frequently used
trajectory analysis on amyloid peptide aggregates simulations are (a) RMSD and RMSF (b)
Secondary structure analysis (c) interstrand distance (d) Intersheet distance (e) hydrogen bond
analysis (f) Cluster analysis and (g) MMPBSA binding free energy calculation
A root mean square distance (RMSD) analysis of the amide backbone atoms is often a
strong indicator of conformational changes of a protein. The root mean square distance (RMSD)
between the backbone atoms of the trajectory frames of polypeptide chains and the
corresponding atoms of the x-ray structure, calculated for the frame t, is given by equation 11,
where xm, ym, zm are the cartesian coordinates found at the X-ray structure and xl yl zl are the
Cartesian coordinates of trajectory frame t. N is the number of atoms.71
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(11)

To obtain information on local structural flexibility, stability, and effect of mutations on the
investigated amyloid peptides molecules a root mean-square fluctuations (RMSF) analysis was
performed.72 RMSF of the C atoms of each residue are calculated as follows: RMSF
RMSF =

(12)

where T is the number of snapshots considered in the time trajectory, ri(t), the position of the C
atom of residue i at time t, and ri, the time-averaged position of the C atom of residue I.73
The secondary structure dynamics shows the conformational change that occurs for a
peptide or protein during the simulation. The commonly used program for analysis of the
secondary structure is the Dictionary of Protein Secondary Structure (DSSP). The DSSP
algorithm was written by Kabsch74 and is based on identification of hydrogen-bonding (Hbonding) patterns and recognizes seven types of secondary structures which can be grouped into
three classes: helix (α-helix, 310-helix, π-helix), β-strand (isolated β-bridge, extended β-sheet)
and loop (turn, bend). We carried out secondary structure analysis using the DSSP tool in
AMBER11.54
To examine the structural stability of the wildtype and the corresponding mutant
oligomers we also analyzed the inter-strand (dstrand) and inter-sheet (dsheet). The dstrand is
calculated by averaging the mass center distance between each residue in one strand and its
corresponding residue in adjacent strand in the same sheet, whereas dsheet is calculated by
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averaging the mass center distance between each strand in one sheet and its corresponding strand
in the adjacent sheet.75
A hydrogen bond is weak electrostatic attraction. It forms when a hydrogen atom
covalently binds to an electronegative atom and is electro-statically attracted to another
(electronegative) atom. The atom to which the hydrogen atom (H) is covalently bound is
considered the hydrogen donor (D), and the other atom is the hydrogen acceptor (A).

In

biological polymers, the donor and acceptor atoms are either nitrogen or oxygen., In protein for
example in helices and sheets, the D–H · ·A sequence is N–H ·· O=C.76 The strength of a
hydrogen bond can be characterized by two geometric quantities which govern the hydrogen
bond energy: hydrogen bond angle, D–H · A atoms and optimal hydrogen bond length, H · ·A
(or D · A) distance.76 Hydrogen bond and hydrogen bond occupancies was calculated using
PTRAJ module available within AMBER. A hydrogen bond is assigned if the distance between
donor D and acceptor A is ≤3.5 Å and the angle D–H · A A≥120o75 using PTRAJ module
available within AMBER.
Cluster analysis (“clustering”) places similar samples of data into groups called clusters,
such that an ensemble of data (for example the different structures obtained from an MD
trajectory) is partitioned into groups of similar objects. Structural clustering is useful for
understanding the molecular motion within conformational space.77 To identify the most
populated conformations sampled, clustering was applied to all snapshots from the trajectories
using the Ptraj program of AMBER11. To perform the clustering, we utilized the average linkage
algorithm implemented in Ptraj.54
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Amyloid fibrils typically exhibit twisted β-sheets and twisting of β-sheets optimize the
hydrogen bonds, side chain stacking, and electrostatic interactions, thus twisted sheets are more
stable than flat ones.
Simone et al
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Twisting angles have been computed by using the method reported by

and Figure 1-2 shows the average twist angle calculation for the Elk prion

segment NNQNTF.

2.5

Binding free energy calculation

Free energy calculation methods have become powerful tools as they can provide
quantitative measurement of protein-ligand or protein-protein interactions. The molecular
mechanic Poison-Boltzman or the generalized born solvent accessible surface area (MMPB(GB)SA)

80, 81

method as implemented in AMBER 11 was used to calculate the binding

energy for non-covalent association of between the studied amyloid peptides. The calculation of
the binding free energy requires three independent MD simulations of the complex and both
individual protein. However an assumption was made that no significant conformational changes
occur upon binding i.e. structural change is negligible and the snap shots for all three species
were obtained from the single trajectory carried out on the complex by separating the complex
into its constituent parts.
The free energy analyses in this thesis was done using a single trajectory approach, where

the complex (C), receptor (B) oligomer aggregate), and ligand (A) snapshots were taken from the
snapshot of the performed MD trajectory. According to the MM-GBSA/MM-PBSA method,80,81
binding free is calculated using equation 11:
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Gbind = GC  -  GA - GB

(11)

The bracket,  , indicates an average of these energy terms over extracted from the MD
simulation.
Gbind = EMM +   Gsolv - TS

(12)

The free energy of each system X=A, B, or C was computed as a sum of the three terms:
ΔGX = EMM + ΔGsolv - TS

(13)

Where EMM is the molecular mechanics energy of the molecule expressed as the sum of the
internal energy (bonds, angles and dihedrals) (Eint), electrostatic energy (Eele) and van der waals
term (Evdw):
EMM = Eint + Eele + Evdw

(14)

∆Gsolv accounts for the solvation energy which can be divided into the polar and nonpolar part:
∆Gsolv = ∆GGB + ∆GSA

(15A)

The polar part ∆GGB accounts for the electrostatic contribution to solvation and is obtained from
Generalized Born (GB) calculations in a continuum model of the solvent. The second term ∆GSA
is nonpolar contribution to solvation free energy that is linearly dependent on the solvent
accessible surface area (SASA):
∆GSA = γSASA + b

(15B)

The ΔGSA were calculated using AMBER11 default parameter for γ and b (15b). The entropic
contribution was calculated in chapter 4 and 6 using the normal mode module in AMBER11.82, 81
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2.6

Application of MD simulation in the study of bimolecular system

Various aspects of protein structure and function have been studied by Molecular
dynamics in numerous fields, including structural biochemistry, biophysics, enzymology,
molecular biology, pharmaceutical chemistry, and biotechnology.50 One notable important area
of application MD simulation is structure aided drug design. Virtual compound screening using
molecular docking is widely used in the discovery of new lead compounds for drug design.
However, this method is not completely reliable and therefore unsatisfactory. Okimoto et al

83

using combined docking and molecular dynamics simulations has found improvement of 1.6 to
4.0 time in enrichment performance compared to docking method. In the study of protein
aggregation MD simulation have provided insight into amyloid structure and aggregation
mechanism.84 MD simulation have been used by various researchers.

85, 86, 87

in order to

understand the mechanism of aggregation inhibitor effects of small organic molecules.
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dstrand=

(9)

A

dsheet=

(10)

Figure 2-1 Schematic definition of inter-sheet and inter-strand distances Adopted from Ref. 75
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Figure 2-2 Schematic definition of the average twist angle. The twisting of SH1-ST5 of
NNQNTF calculated by determining the dihedral angle from the coordinates of the 2nd and the
5th Cα-atom of the first and the last strand of the sheet. The calculated angle provides a measure
of the overall twisting of each sheet. The twist angles were calculated by using the three inner
strands and the average twist angles between consecutive strands were estimated by dividing the
twist by three. 88
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Figure 2-3 Thermodynamic cycle in MM-PB(GB)SA calculations. The gray surface represents
the aqueous solvent.
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CHAPTER 3
STERIC ZIPPER STABILITY IN WILDTYPE AND
MUTANTS OF THREE AMYLOID FRAGMENTS

Chapter 3, in part, is a reprint of the material as it appears in Journal of Molecular
Modeling,2011, Workalemahu M. Berhanu  Artem E. Masunov, published online: 21 Dec.
2010; DOI 10.1007/s00894-010-0912-4

3.1

Background

Aggregation of polypeptide chains and formation of amyloid fibrils are associated with
the development of a number of disorders, including Alzheimer‟s, Parkinson‟s, type II diabetes,
and Creutzfeldt-Jakob disease.

89

Amyloid deposits develop when proteins misfold out of their

native conformations and aggregate into insoluble fibrils.90 The amyloid fibrils share a sequence
independent structure characterized by cross-β spine structural motif in which protein β-strands
run orthogonal to the fibril axis and repetitive hydrogen bonding extends parallel to the axis.91, 92
This cross-β spine may correspond to the global minimum energy conformation for a wide
variety of proteins.91 Identifying this structural motif in small model peptide systems and
characterizing it under different conditions can yield valuable clues about the molecular-level
details of amyloid formation. Recently, the microcrystal structures of several amyloidogenic
peptides have been determined by x-ray crystallography.22, 93, 94 These high resolution structures
provided researchers with a unique opportunity to understand the structural details and on the
factors that destabilize/stabilize the amyloid fibrils. Molecular dynamics (MD) simulations,
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along with other theoretical approaches, based on these crystal structures, can often present
significant contribution to this understanding.79, 95-103 By selecting an amyloid oligomer out of
the crystal structure and evaluating its conformational stability in a crystal-free environment,
these investigations have provided insights into the intrinsic propensities of peptide fragments to
associate in amyloid-like states, the energetic factors stabilizing these aggregates, and the
possible aggregation states of oligomeric precursors or larger assemblies up to 128 β-strands.
One of the common structural features, observed in many available X-ray structures of
amyloidogenic polypeptides is pairing of the β-sheets by interdigitated side chains in a dry „steric
zipper‟. It is worth noting, that most of the theoretical investigations have been conducted on the
systems where steric zipper interface is composed of the large polar and/or aromatic side chains.
In this study we focus on aggregates stabilized by steric zipper interfaces formed by small
hydrophobic residues (VQIVYK, MVGGVV) (Figure 3-1). A system with polar H-bonding side
chains (LYQLEN) (Figure 3-1) is also considered for comparison. We perform all-atom MD
simulations with explicit solvent on both wild type and mutant polypeptides at various degrees of
aggregation. The initial structure of the aggregates is based high resolution X-ray study.22 The
MVGGVV peptide represent the fragment (residues 35-40) from the C terminal of the A1-40
peptide, associated with Alzheimer‟s disease.104, 105 The VQIVYK is a fragment (residues 306311) of the Tau protein, which is also involved in the pathogenesis of Alzheimer‟s disease.
LYQLEN peptide is a fragment of a chain (residues 13-18) of Insulin that had been shown to
form amyloid-like fibrils.22
In Alzheimer‟s disease (AD), the Tau protein forms intracellular amyloid tangles in
neurons.106, 107 The hexapeptide VQIVYK models the key amyloidogenic peptide sequence and
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forms amyloid-like fibrils with the same cross- structure found in full Tau amyloid fibrils.22
The structural organization of VQIVYK is a parallel β-strand within the same β-sheet layer while
maintaining anti-parallel organization between the adjacent β-sheet layers.22 At the dry interface
between the adjacent β-sheet layers, the shape complementarity is formed by the hydrpbobic
steric zipper via the side chains of Val1, Ile3 and Tyr5 (Figure 3-2a)

22

, packing against each

other forming the sheet-sheet interface. Aggregation of A peptides, which are the natural
products of cellular proteolytic, is also linked to Alzheimer‟s disease (AD). The most abundant
A species are 40 residue peptides (A1-40). The MVGGVV peptide is a fragment (residue 3540) from the C terminal of the A1-40 consists of parallel and anti-parallel -strands within the
same -sheet layers. At the dry interface between the adjacent -sheet layers, the shape
complementarily is formed by the hydrophobic steric zipper via the side chains of Met1, Val2
and Val5 (Figure 3-2b, c). 22
Fibrils of Insulin are observed extracellularly in the rare medical condition termed
injection amyloidosis. These Insulin fibrils formed in vivo display the defining characteristics of
amyloid aggregates such as binding the dye Congo red

30

and the cross- X-ray diffraction

pattern.29 Both A chain and B chain can form fibrils on their own 108, 109, and seeds of A chain or
B chain can nucleate the fibrillation of full length Insulin.108 The atomic-resolution picture of the
interactions between segments of Insulin which may be part of fibrillar spine came from crystal
structures of the fibril forming peptide segments LYQLEN (residues A13–A18) and VEALYL
(residues B12–B17).22 The structural organization of LYQLEN is anti-parallel β-strands within
the same β–sheet layer while maintaining parallel organization between the adjacent β-sheet
layers.22 At the dry interface between the adjacent β-sheet layers, the shape complementarity is
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formed by the polar side chain steric zipper (Tyr2, Gln3, Leu4 and Asn6) and side chain Hbonding (Figure 3-2d).22 Recently, serum samples from patients with Parkinson‟s disease have
been found to display an autoimmune response to Insulin oligomers and fibrils

110

, possibly

indicating the presence of Insulin aggregates in this disease as well. Insulin also reported to form
amyloid-like fibrils in vitro under elevated temperatures, low pH, and increased ionic
strength.111, 112 This fibril formation has been a limiting factor in long-term storage of Insulin for
treatment of diabetes. Thus, better understanding of Insulin fibrillation could lead to safer
handling and more cost-effective storage of Insulin.
Previous theoretical study has demonstrated the significant role of steric zipper in the
structural stability of the GNNQQNY and GGVVIA oligomers stabilized with polar side chain
and H-bonding.102, 113 Park et al. 95 address the structural selection mechanism of different double
layer peptides including GNNQQNY, NNQQ, VEALYL, KLVFFAE and STVIIE, and find that
the patterns with the lowest binding free energy correspond to X-Ray structures with high
accuracy. The main contribution of the binding free energy of the double layer pattern is
determined by the van der Waals and hydrophobic forces. These contributions can therefore
serve as a quantitative measure of shape complementarity among side chains between the βsheets. The steric self-complementary (known as steric zipper) selects the most stable packing
modes. It also makes parallel β-sheets generally preferred over anti-parallel ones. The presence
of charged side chains appears to give anti-parallel β-sheets kinetic preference at the early stages
of assembly, while the double layer formation is likely to be thermodynamically controlled. Xu
et al.

114

investigated the β-sheets composed of seven antiparallel decapeptides, representing the

20–29 segment of human Islet amyloid polypeptide (hIAPP). The amyloid nucleus of hIAPP was
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mimicked with one -sheet of different initial separation distances between the strands. Multiple
all-atom MD simulations with explicit water solvent showed that the assembly occurs not only in
the lateral direction but also along the longitudinal direction. This provides a new insight into the
assembly pathway at the early stage of fibril elongation. Based on the Poisson–Boltzmann free
energy analysis and quasiharmonic configuration entropy estimation, the entropic contribution
was found to play an important role in the longitudinal assembly. Moreover, a possible
oligomeric state with cyclic form was suggested based on one assembly model found in the
simulations. This evidenced the polymorphic nature of the amyloidogenic oligomerization and
possible mechanism of its toxicity. The cyclic structures of amyloid oligomers have been
reported to be the early intermediates in solution, capable to form ion-channel-like structures in
the membrane that could be responsible for pathologic membrane permeability and
destabilization of the cellular ionic homeostasis.115, 12
Vitagliano et al

116

in their molecular dynamics simulation characterizing assemblies

formed by steric zipper assemblies composed of a pair of 10-stranded -sheets of the peptides
SSTSAA and VQIVYK show high fluctuations and significant distortion. The analysis of the
VQIVYK crystal packing reveals two different double layers with significant interface area and
surface complementarity.22 One is characterized by nonpolar dry interface made up essentially
by the side chains of V1 and I3 of the two layers, while the other is polar and involves Tyr and
Gln side chains.22 The nonpolar interface exhibits larger values of the surface area (113 vs. 89
Å2), but slightly lower surface complementarity (0.76 vs. 0.82).22 The stability of the nonpolar
hydrophobic interfaces was studied by Vitagliano et al. 116 in their MD simulations. They report
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high fluctuations and significant distortion (RMSD c.a. 10 Å within 40 ns simulation) when
investigate three layer assemblies formed by steric zipper and composed of a pair of 10-stranded
-sheets of the peptides VQIVYK. In the contrast, they found RMSD below 6 Å within 40 ns
simulation, when study the 10-stranded double layer with nonpolar interface. Hence, the stability
of the nonpolar interface is system dependent.
However, the atomic information for the early stage of the aggregation mechanism of the
VQIVYK, MVGGVV and LYQLEN peptide is still limited so far. Thus, understanding the
structural stability and aggregation behavior of the VQIVYK, MVGGVV and LYQLEN peptide
is expected to provide knowledge for designing an inhibitor aimed to decrease the selfaggregation into fibrils.
In this study, several all-atom MD simulations with explicit water at 300 K were
conducted to investigate the structural stability, aggregation behavior and thermodynamics of the
VQIVYK, MVGGVV and LYQLEN peptides with various sizes and its single glycine
replacement mutations. Our aim is to elucidate: (i) the influence of the number of the peptides on
the structural stability and conformational dynamics of the oligomers; (ii) the possible minimal
nucleus seed for the fibril formation of the peptides; (iii) the principle driving force for the
association of the peptides; and (iv) the effects of single glycine replacement mutations on the
structural stability of the oligomers. The results of this study may provide insight into the
possible mechanism of fibrillogenesis of the amyloid peptides. It may also be helpful for
designing new or modified capping peptides capable of breaking the driving force for
aggregations and preventing the fibril formation of the peptides.
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3.2

Methods

The crystal structure of the VQIVYK, MVGGVV and LYQLEN had been determined by
Sawaya et al.22 The atomic coordinates of the multiple unit cells were taken from the website 117,
and the water molecules from the crystal structure were removed. The MVGGVV have two
different polymorphic forms (form 1 and 2 with resolution of 2.0 Å and 1.8 Å) both of which
were used in the simulation. The Sirius visualization program from San Diego Supercomputer
Center (http://sirius.sdsc.edu) was used to construct the aggregates of various sizes. The initial
geometry of the largest aggregate was taken as a pair of -sheets composed of 6 strands (5
strands for VQIVYK), it is shown on Figure 3-2. In the following we denote the aggregates ShNStM, where N is the number of -sheets, and M is the number of strands per -sheet. The initial
geometry of the largest wild type aggregate was taken as a pair of -sheets composed of 6
strands (MVGGVV and LYQLEN) and 5 strands (VQIVYK), as shown on Figure 3-2. For the
smaller size wild type systems, the initial structures of oligomers were obtained by removing the
β-strands one by one from the Sh2-St5 (VQIVYK) or Sh2-St6 (MVGGVV and LYQLEN)
models. To construct the mutant systems, several glycine replacements were made in the wild
type aggregate. The mutants are denoted as XnG, where X is the replaced residue, and n is its
position in the peptide sequence. Three or four mutants were designed for each peptide (V1G,
I3G, and Y6G for VQIVYK; M1G, V2G, V5G, and V6G for MVGGVV; V2G, Q3G, L4G and
V6G for LYQLEN). The simulation details for each model are summarized in Table 3-1, 3-2, 3-3
and 3-4. The MM-PBSA single trajectory approach implemented as script in Amber10.

118

was

used to calculate the steric zippers binding energy for non-covalent association between the 57

sheets within the double layer. The gas phase and the solvation free energies were calculated
over 500 snapshots taken at 20 ps intervals from the last 8 ns of the MD trajectories.

3.3
3.3.1

Results

Size dependent structural stability of the wild type peptides aggregates

Eight simulations of wild type VQIVYK were conducted for the aggregates build of one
(models A1-A4) and two (models A5–A8) antiparallel β-sheets with parallel strands within each
sheet. The relative stability of the model aggregates was measured by the backbone root meansquared deviation (RMSD). The reference structure for calculating backbone RMSD was the
energy-minimized structure. As one can see on Figure 3-3A, for the model systems of A1 (Sh1St2) and A2 (Sh1-St3), the RMSDs remained below 2.Å for 10 ns, while for A3 (Sh1-St4) and
A4 (Sh1-St5) the RMSDs increased to 4.5Å, indicating the lower relative instability of the one
layer aggregate with larger number of strands. The larger two-layer model systems of A7 (Sh2St4) and A8 (Sh2-St5), maintained RMSDs c.a. 4.0 Å within 10 ns, indicating relative stability
of the structures compared to the smaller bilayer models A5 (Sh2-St2) and A6 (Sh2-St3), which
showed large fluctuations up to 7.0 Å (Figure 3-4A). The results of two-layer models suggested
that the structural stability of the VQIVYK oligomers increases with increasing the numbers of
β-strands, the four and five stands are more stable than two and three strands, while for one-layer
models the trend is opposite.
Our simulation for 5-stranded double layers of the wildtype VQIVYK oligomers was
found to have a RMSD of 4 Å, in good agreement with the result reported by Vitagliano et al.116
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The comparison of the RMSD values of the nonpolar interface models (VQIVYK and
MVGGVV) with LYQLEN that has polar residues on the dry interface indicates the nonpolar are
significantly less stable. The smaller RMSD values of the polar LYQLEN is in a good agreement
with the result of Zhang et al.113, who found an RMSD of 2 Å by simulation of 4-stranded double
layer GGNNQQNY, which has polar residues on the dry interlayer interface. Our results indicate
that the polar dry interface significantly improves stability.
Another eight wild type simulations of MVGGVV1 (models C1–C8) were conducted for
anti-parallel β-sheets with parallel strands within the sheets. As shown in Figure 3-3B, for the
model systems of C1 (Sh1-St2) and C2 (Sh1-St3), the RMSDs were below 4.50 Å within 10 ns.
For C3 (Sh1-St4) and C4 (Sh1-St5) the RMSDs were maintained below 4.5 Å and 6 Å within 10
ns respectively, the two layer model systems of C7 (Sh2-St4) and C8 (Sh2-St5), the RMSDs
were below 3.0 Å within 10 ns as shown in Figure 3-4B. Aggregate C6 (Sh2-St2) maintained
RMSDs below 4.0 and C5 (Sh2-St3) showed large fluctuations RMSD within the first 5 ns and
then increased to 12 Å after 7 ns. Our results for one-layer models suggest that the structural
stability of the MVGGVV1 oligomers increases as the number of stands decreases, while the
results of two-layer models suggest that the structural stability of the MVGGVV1 oligomers
increases remarkably with increasing the numbers of β-strands, the four and five stands are more
stable than two and three strands.
Four wild type MVGGVV2 peptide aggregates (two layer with different number of
strands), simulations were conducted for antiparallel β-sheets with parallel strands within the
sheets (models E1–E4). We did not do single layer simulation, assuming the result will be the
same as for polymorphic form I. As shown in Figure 3-4C, E2 (Sh2-St3) and E3 (Sh2-St4), the
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RMSDs were almost identical and remained < 6.0 Å within 10 ns. While E1 (Sh2-St2) showed a
large fluctuations within 1ns and remained c.a. 7.0 Å within 10 ns. E4 (Sh2-St5) shows the same
RMSD change as E2 and E3 for the first 4ns increasing to ~5.0 Å and maintained an RMSD 
5.0 Å during the 10 ns simulation. The results of two-layer models suggested that the structural
stability of the MVGGVV2 oligomers increases with increasing the numbers of β-strands, the
four and five stands are more stable than two and three strands.
Finally eight wild type LYQLEN peptide aggregates (models G1–G8) were considered
for antiparallel β-sheets, parallel strands within the sheets. As shown in Figure 3-3C, for the
model systems G1 (Sh1-St2), G2 (Sh1-St3), G3 (Sh1-St4) and G4 (Sh1-St5) consisting of one
layer and different number of strands, the RMSDs remained at 2.0 Å within 10 ns, indicating
exceptional stability of these structures. Figure 3-4D show that for the model systems G5 (Sh2St2) and G7 (Sh2-St4), the RMSDs showed were maintained at ~4.50 Å, for G8 (Sh2-St5)
RMSDs is c.a. 2.50 Å, and for G6 (Sh2-St3) RMSD demonstrates a large fluctuation within the
first 4 ns and then stabilized at 7 Å after 8 ns, which indicated that they lost their original
structural organization. The results of two-layer models suggested that the structural stability of
the LYQLEN oligomers increases remarkably with increasing the numbers of β-strands, with
four and five stands being the most stable. Our results for one-layer models suggested that the
structural stability of the LYQLEN oligomers is the same irrespective of the number of strands.
One layer with two, three, four and five stands (model G1-G4) are structurally stable with
RMSD c.a 2.0 Å. The LYQLEN oligomers is stabilized with backbone to backbone and side
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chain hydrogen bonding while in the case of the VQIVYK , MVGGVV1 and MVGGVV 2 are
stabilized with back bone to back to bone hydrogen bonding.
Comparing single and double layer models, our results reveal that the extra β-sheet strand
contributes significantly to the structural stability of the VQIVYK, MVGGVV1 and MVGGVV2
oligomers for double layer model while in the case of single layer model it decrease. In the case
of the LYQLEN our results also shows that an extra β-sheet strands contributes significantly to
the structural stability of the LYQLEN oligomers for double layer models while in the case of
single layer model it is almost the same irrespective of the number of strands. This is in
agreement to previous studies done on different types of amyloid models. The above results all
together suggest that the structural stability of the oligomers increases significantly with
increasing the number of β-strands for double layer models implying extra sheet-sheet
interactions are necessary for the formation of steric zipper to associate the strands, resulting in
more stable oligomeric organizations. Our findings are in agreements with previous observations
102, 113

which indicate that the minimal nucleus seed for the amyloid fibril formation could be as

small as three or four peptides.
The evolution of the root mean square deviations (RMSDs) between initial and the
current trajectory structures indicates that the system undergoes certain rearrangement. The
initial structures are taken from X-ray and may be stabilized by the crystal environment.
However, the simulations are performed in the solution state. Due to this different environment,
relatively large RMSDs may not always correspond to the unstable structures. To further analyze
the structural stability we also performed secondary structure analysis and binding free energy
calculations.
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3.3.2 The effect of single-glycine mutations on structural stabilities of the aggregates
To investigate how the steric zipper interfaces influence the structural stability of the
double-sheet aggregates of VQIVYK, MVGGVV and LYQLEN peptides, the side-chains
participating in these interfaces were replaced by glycine (Table 3-1 to 3-4). As one can see from
the Figure 3-5A, the largest aggregates composed of these mutants were less stable, compared to
the respective wild type aggregates. The RMSD of I3G and Y5G are somewhat higher (c.a
5.5Å), than those of V1G (c.a. 4.5Å), indicating that I3G and Y5G exhibit higher potential to
destabilize the structure of the VQIVYK aggregate. Mutations of the nonpolar side chain Ile-3 or
Tyr-5 to Gly were found to result in destabilization of the oligomeric structures. Figure 3-5B
indicates that none of MVGGVV1 mutants were structurally stable compared to the value of the
respective wild type model. It shows that the RMSD of M1G and V6G are significantly higher (<
8.5 Å) than those of V2G and V5G (< 5.5.Å), indicating that V2G and V5G exhibit higher
potential to destabilize the structural integrity of the MVGGVV1 oligomer. The result also
(Figure 3-5B), shows that mutation of the non polar side chain Met-1 or Val-6 to Gly negatively
affects the intersheet steric zipper destabilizing the structural integrity of the MVGGVV1
oligomers to a greater extent than the V2G and V5G mutants and the wild type. Figure 3-5C
shows that some of MVGGVV2 mutants (V2G and V6G) were structurally stable compared to
the wild type model. It shows that the RMSD of the mutant V2G and V6G are lower (nearly 4.0
Å) than those of M1G and wild type (nearly 6.0 Å), indicating that V2G and V6G exhibit higher
potential to stabilize the structural integrity of the MVGGVV2 oligomer. The result also shows
(Figure 3-5C), that Y5G (RMSD > 15.0 Å) destabilize the structural integrity of the MVGGVV2
oligomers to a greater extent than the other mutants and the wild type. Our finding that the
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MVGGVV2 wild type aggregates are less stable compared to certain mutants is in contrast to
other oligomers in our study and to conclusions of the previous work done on the hexapeptide
amyloid.102, 113 This apparent contraction could be explained based on the structural difference
between this particular polymorph and other amyloid X–ray structure in that there is 900 bending
in the upper sheet of MVGGVV form 2.22 As can be seen in Figure 3-5D, none of the mutants of
LYQLEN are as structurally stable as the wild type, indicating that the side chain interactions
play an important role in determining the stability of the LYQLEN oligomers. However, the
N6G mutant have small RMSD values (2.5 Å), whereas the Y2G, Q3G and L4G mutants have
large RMSD values (> 4.0Å). Comparison between the dynamics of the wild type and its mutants
suggests that mutations N6G have little effect on the structural stability of the LYQLEN (low
RMSD), whereas mutations Y2G, Q3G and L4G destabilize the oligomeric structures. The
destabilization of the Q3G and L4G mutants is even more pronounced. As seen in Figure 3-5D
mutations of the polar side chain Gln-3, or Leu-4 to Gly would affect the inter sheet steric zipper,
leading to greater destabilization of the oligomeric structures.

3.3.3

Secondary Structure Assessment

We analyzed the secondary structure of the oligomers using the DSSP algorithm written
by Kabsch and Sander.74 This algorithm is based on identification of hydrogen-bonding (Hbonding) patterns and recognizes seven types of secondary structures which can be grouped into
three classes: helix (-helix, 310-helix, π-helix), β-strand (isolated β-bridge, extended β-sheet)
and loop (turn, bend). The result of the secondary structure analysis for a two layers models of
the amyloid peptides show that the wild type of Tau (St2-St5 VQIVYK), Insulin (St2-St6
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LYQLEN) and Aβ amyloids Polymorphic form I and II (Sht2-St6 MVGGVV) appear to be
stable at 300K, which is confirmed by the conservation of high anti-parallel β-sheet content
throughout the whole simulation time (as shown in Figures 3-6A-D). In all systems the contents
of antiparallel β sheets are much greater than the turn or parallel β-sheet indicating the
conservation of the original structure. The results also indicate that antiparallel β-sheet, parallel
β-sheet and turn content were preserved throughout the 10 ns simulation. The analyses of the
secondary structure evolution throughout the simulation for the mutant form of the amyloids are
shown in Figures 3-6 to 3.9.
The results for Tau mutant and the wild type the secondary structure is shown in Figure
3-6A. In the case of the Tau mutants the content of the secondary structure declined specially in
the last 3ns of the simulation. This result is in agreement with the RMSD results discussed
above. The decline is largest in I3G which has the largest RMSD value. Figure 3-7B shows the
results for Aβ peptide polymorph form I for both the wild type and mutants. The result for the
wild type shows that the secondary structure is preserved as indicated with its high and content
of antiparallel β-sheets (~0.7). Among the mutants the content of the secondary structure was
more unstable for M1G indicating the greater destabilizing effects of replacing methione with
glycine. This is in agreement with the RMSD result, the highest RMSD among the mutants was
from the M1G mutant (see Figure 3-6B). Figure 3-8C shows the results for Aβ peptide
polymorph form II for both the wild type and mutants. The result for the wild type shows that the
secondary structure is preserved as indicated with its high and content of antiparallel β-sheets
(~0.7). Among the mutants the content of the secondary structure was more unstable for M1G
indicating the greater destabilizing effects of replacing methione with glycine. This is in
64

agreement with the RMSD result, the highest RMSD among the mutants was from the M1G
mutant (see Figure 3-8B).
The results for Insulin amyloid mutants (Figure 3-9D) and the wild type shows that the
secondary structure is preserved as indicated with its high content antiparallel β–sheets (~0.7). In
the case of the Q3G and Y2G mutants the content of antiparallel β-sheets declined specially in
the last 2 ns of the simulation. This result is in agreement with the RMSD results. The RMSD for
both Q3G and Y2G mutants was the largest ~5 Å.
Two trajectory snapshots (at 5 ns and 10ns) are shown in Figures 3-10 to 3-13 for each of
the two layer oligomer aggregates. As the structure evolves, some of the terminal strands break
the β-sheet ordering and twist relative to the remaining strands although do not dissociate from
the aggregate completely. Degree of this disorder correlates with the RMSD values reported on
Figures 3-3 to 3-5. Among the most disordered structures are mutant I3G of the Tau fragment
(VQIVYK), mutants V6G and M1G of the A fragment polymorph 1 (MVGGVV1) mutant V5G
of the A fragment polymorph 2 (MVGGVV2) and the mutants Y2G and Q3G of the Insulin
amyloid (LYQLEN). Apparently, the mutated amino acids were involved in the steric zippers,
which were not holding the β-sheets together, but also preserving them from disaggregation.
Inversely, the complementarity of the amino acids sidechains would be essential for the
formation of the ordered aggregate. On the other hand, disordered random aggregation may take
place for any polypeptide studied in this work, as suggested by the negative values of association
free energies, reported in the next section.
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3.3.4

Free energy calculations

The binding free energies were calculated with the Molecular Mechanics Poisson-Boltzmann
solvent accessible surface area (MM-PBSA) model
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, as implemented in AMBER. In this

method, the total binding free energy in water is approximated by ΔGTOT = ΔEGAS + ΔGPB +
ΔGSUR. The ΔEGAS is the gas phase interaction energy. The ΔGPB/GB is the polar part of the
solvation free energy represented by Poisson-Boltzmann approaches. The ΔGSUR is the surface
area term, approximating the non-polar part of the solvation free energy. In this formula, the
conformational entropy of the solute is not considered, while the solvent entropy is implicitly
considered in the ΔGPB and ΔGSUR. Although the MM-PBSA calculations may overestimate the
absolute binding free energy due to the missing terms (e.g., conformational entropy change of
the solute upon binding), they usually give a reasonable estimate on the relative binding free
energy when the conformational entropy changes of two binding modes are comparable 119.
The binding energy was calculated by MM-PBSA method and is specified in method
section. The breakdown of binding energy components is listed in Table 3-4 to 3-7. The MMPBSA analysis allows us to separate the total free energy of binding into electrostatic, van der
Waals interactions and solute-solvent interactions, and thereby gain additional insights into the
monomer to monomer association process in the formation of the dimer of the amyloid
oligomers. As shown in Table 3-4 and 3-7, van der Waals interactions play a very important role
in the simulation, contributing significantly more to the total interaction energy than the
electrostatic interaction for the Tau (VQIVYK) and Insulin (LYQLEN) aggregates. Nonpolar
solvation energies favor the binding and the polar solvation energies disfavor it. In the case of
Aβ oligomers, MVGGVV, electrostatic interaction play a very important role in the simulation,
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contributing significantly more to the total interaction energy than the van der Waals interactions
(Table 3-5 and 3-6). Nonpolar solvation energies favor the binding and the polar solvation
energies disfavor it. Note that the internal component of the molecular-mechanical energy (bond,
angle, and torsional energies) has zero contribution to the binding free energy, because the
structures of the monomers in its unbound and bound states were assumed to be the same (data
not shown). Table 3-4 to 3-7 also reports the contributions of apolar/hydrophobic and
polar/electrostatic to the free energy. We found that the predicted binding free energy is
dominated by the magnitudes of the apolar components (ΔEvdw + ΔEsur) in all the four oligomers
and their mutants. In contrast, the polar interactions (ΔEelec + ΔGPB) show less contribution to the
binding free energy. The result of the binding free energy calculation also indicated that the wild
type is the most stable structure compared to the mutants. From the negative total binding free
energy of the wild types we clearly see that this is a favorable protein-protein complex in pure
water. The mutants also form a stable complex based on the negative total binding free energy.
However, the mutant complex is less thermodynamically favorable than the wild type complex.
The calculation indicated that the mutation of bulky polar side chain from the steric zipper
structure leads to the less stable dimer (see example Table 3-4 to 3-7) giving mutant with
smallest binding free energy, and indicating that these residues are important for stabilizing the
structure.
The widely accepted hypothesis on the amyloid disease is that soluble protein oligomers
are the source for toxicity and are the primary pathogenic factor in these diseases and thus small
molecules that prevent or reverse protein oligomerization may provide a mechanism to target the
actual cause of the disease

120, 121

. Peptidomimetics are promising class of small molecules
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capable of inhibiting oligomerization. Most fibrillogenesis inhibitors of this type were designed
rationally based on molecular recognition elements found in the site of aggregation.122
Identification of this aggregation site is often based on the mutational data. Such data helps to
pinpoint the small regions on the protein interaction interface that are responsible for a
disproportionate contribution to the binding energy of the two proteins.123-125 In this work we
have shown that most mutations at the aggregation site reduce the binding free energy and
weaken the aggregation. Therefore, the computational studies can serve the same purpose of the
rational design, as experimental mutation studies.
Another potential application of the presented approach is design of imaging agents.
The progress in therapeutic agents for treatment of neurodegenerative amyloid diseases calls for
development of more specific biomarkers to detect early stages of amyloid diseases.126 Design of
peptidomimetics based on the data obtained in the molecular dynamic simulation may provide
the starting point for design of specific aggregation inhibitors drugs and diagnostic agents. Both
structural and thermodynamic results reported in this study illustrate the higher fluctuation in
RMSD values and less negative binding free energies for the mutated peptides. These mutants,
therefore, may serve as aggregation inhibitors pending the experimental confirmation.

3.4

Conclusions

The major findings of this study can be summarized as follows:
1.

The stability of the VQIVYK, MVGGVV and LYQLEN peptides oligomers increases

with increasing the number of β-strand;
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2.

The Sh2-St4 model acts as a stable seed in prompting amyloid fibril formation for all the

cases considered;
3.

The binding energy calculated by MM-PBSA method and the analysis of individual

contributions to the binding energy shows the hydrophobic interactions play an important role in
stabilizing the structural organizations between β-sheet layers in the oligomers. The result of the
binding free energy calculation also indicated that the wild type is the most stable structure
compared to the mutants;
4.

The hydrophobic steric zipper on the intersheet interface contributes significantly to the

stability of the entire aggregate structures. Mutations of the side-chains participating in the steric
zipper interfaces of the oligomeric (VQIVYK, MVGGVV1 and LYQLEN) peptides to Gly
resulted in decline of secondary structure content compared to corresponding wild type
indicating that the role of the replaced amino acid in stabilizing the structure;
5.

A single glycine substitution at the steric zipper interface disrupts the hydrophobic steric

zipper remarkably, indicating that the hydrophobic attraction is a major driving force for
stabilizing and aggregation of oligomers. Consequently, the substantial reduction in the van der
Waals intersheet interactions leads to destabilization of the oligomers. Overall, aggregation of
both wild type and mutant peptides is driven by nonpolar interaction.
Some evidence from the experimental work suggests that short peptides may share
similar intermolecular interactions to their parent proteins while forming amyloid fibril.127 Thus,
exploring the structural stability and aggregation behavior of the short peptides may gain insights
into the self-assembly process at the early stage of fibril formation and provide a clue to
understand the possible aggregation mechanism of their parent proteins. The hexapeptide
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NFGAIL, a fragment truncated from human islet amyloid polypeptide (hIAPP, residues 22–27),
is one of the shortest fragments that have been shown to form amyloid fibrils similar to those
formed by the full polypeptide

127

and the fibrils are cytotoxic toward the pancreatic cell line.

Therefore, this hIAPP „„amyloid-core‟‟ peptide has been used as a simplified model system to
facilitate the discovery of key factors underlying amyloid fibril formation and the development
of anti-amyloid agents. Porat et al

128

showed that whereas the NFGAIL was a minimal fibril

forming fragment from hIAPP with Tyr substituted for Phe (i.e.
22

22

NFGAILSS29 to

NYGAILSS29 did not form fibrils by itself and even inhibited fibril formation. Along these

lines one can envision a possible strategy to inhibit the formation of early aggregates that
includes the design of specific inhibitor, breaking the hydrophobic steric zipper observed in the
structure of hydrophobic region of the amyloid aggregate. Proof of principle for such a strategy
has been published recently.129,130 Thus, designing new peptidomimetic inhibitors able to prevent
the fibril formation based on the steric zipper motif of the oligomers, similar to the ones
examined in this study may become a viable therapeutic strategy. The peptidomimetic approach
can also be implemented in designing specific biomarkers for early stage detection of aggregate
formation.130,131
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Table 3-1 Summary of the VQIVYK oligomer models and simulation system
Model
Wilde type
A1 (Sh1-St2)
A2 (Sh1-St3)
A3 (Sh1-St4)
A4 (Sh1-St5)
A5 (Sh2-St2)
A6 (Sh2-St3)
A7 (Sh2-St4)
A8 (Sh2-St5)
VQIVYK (Sh2-St5)
Mutants
B1
B2
B3

Systems

Sheet/strand organization

sheet1,
sheet1,
sheet1,
sheet1,
sheet2,
sheet2,
sheet2,
sheet2,
sheet2,

----/parallel
----/parallel
----/parallel
----/parallel
Antiparallel / Parallel
Antiparallel / Parallel
Antiparallel / Parallel
Antiparallel / Parallel
Antiparallel / Parallel
Antiparallel / Parallel
Antiparallel / Parallel
Antiparallel / Parallel

strands2
strands3
strands4
strands5
strands2
strands3
strands4
strands5
strands5

sheet2, strands5, V1G
sheet2, strands5, I3G
sheet2, strands5, Y5G
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Simulation box size (Å)

Simulation time (ns)

T(K)

49.31× 49.31 ×49.31
50.84×50.84×50.84
51.67×51.67×51.67
54.06×54.06×54.06
60.97×60.97×60.97
63.36×63.36×63.36
64.84×64.84×64.84
65.88 ×65.88×65.88
65.88 ×65.88×65.88

10
10
10
10
10
10
10
10
10

300
300
300
300
300
300
300
300
300

65.74×65.74×65.74
65.71×65.71×65.71
65.26×65.26×65.26

10
10
10

300
300
300

Table 3-2 Summary of MVGGVV1 oligomer models and simulation system
Model
Wilde type
C1 (Sh1-St2)
C2 (Sh1-St3)
C3 (Sh1-St4)
C4 (Sh1-St5)
C5 (Sh2-St2)
C6 (Sh2-St3)
C7 Sh2-St4)
C8 (Sh2-St5)
MVGGVV1
(Sh2-St6)
Mutants
D1
D2
D3
D4

Systems

Sheet/strand organization

Simulation box size (Å)

sheet1, strands2
sheet1, strands3
sheet1, strands4
sheet1, strands 5
sheet2, strands2
sheet2, strands3
sheet2, strands4
sheet2, strands5
sheet2, strands6

----/antiparallel
----/antiparallel
----/antiparallel
----/antiparallel
Antiparallel / Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel / Antiparallel
Antiparallel / Antiparallel

sheet2, strands6, M1G
sheet2, strands6, V2G
sheet2, strands6, V5G
sheet2, strands6, V6G

Antiparallel / Antiparallel
Antiparallel / Antiparallel
Antiparallel / Antiparallel
Antiparallel / Antiparallel
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Simulation time (ns)

T(K)

52.59×52.59 ×52.59
53.46×53.46×53.46
54.14×54.14×54.14
56.05×56.05×56.05
63.02×63.02×63.02
63.17×63.17×63.17
66.36×66.36×66.36
67.13 ×67.13×67.13
69.17 ×69.17×69.17

10
10
10
10
10
10
10
10
10

300
300
300
300
300
300
300
300
300

69.16 ×69.16×69.16
69.02×69.02×69.02
69.45×69.45×69.45
68.78 ×68.78×68.78

10
10
10
10

300
300
300
300

Table 3-3 Summary of the MVGGVV2 models and simulation system
Model
Wilde type
E1 (Sh2-St2)
E2 (Sh2-St3)
E3 (Sh2-St3)
E4 (Sh2-St5)
MVGGVV2 (Sh2-St6)
Mutants
F1
F2
F3
F4

Systems

Sheet/strand organization

Simulation box size (Å )

sheet2, strands2
sheet2, strands3
sheet2, strands4
sheet2, strands5
sheet2, strands6

Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel

sheet2, strands6, M1G
sheet2, strands6, V2G
sheet2, strands6, V5G
sheet2, strands6, V6G

Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
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Simulation time (ns)

T(K)

60.58 ×60.58×60.58
61.70 ×61.70×61.70
63.24 ×63.24×63.24
64.50 ×64.50×64.50
66.83 ×66.83×68.83

10
10
10
10
10

300
300
300
300
300

64.15 ×64.15×64.15
68.86×68.86×68.86
66.40×66.40×66.40
66.25 ×66.25×66.25

10
10
10
10

300
300
300
300

Table 3-4 Summary of the LYQLEN oligomer models and simulation system
Model
Wilde type
G1(Sh1-St2)
G2(Sh1-St3)
G3(Sh1-St42)
G4(Sh1-St5)
G5(Sh2-St2)
G6(Sh2-St3)
G7(Sh2-St4)
G8(Sh2-St5)
LYQLEN(Sh2-St6)
Mutants
Y2G
Q3G
L4G
N6G

Systems

Sheet/strand organization

sheet1, strands2
sheet1, strands3
sheet1,strands 4
sheet1, strands5
sheet2, strands2
sheet2, strands3
sheet2, strands4
sheet2, strands5
sheet2, strands6

----/antiparallel
----/antiparallel
----/antiparallel
----/antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel

sheet2, strands6, Y2G
sheet2, strands6, Q3G
sheet2, strands6, L4G
sheet2, strands6, V6G

Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
Antiparallel /Antiparallel
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Simulation box size (Å)

Simulation time (ns)

T(K)

50.43×50.43 ×50.43
51.95×51.95×51.95
51.93×51.93×51.93
55.75×55.75×55.75
65.67×65.67×65.67
66.97×66.97×66.97
68.59×68.59×68.59
69.82 ×69.82×69.82
70.46×70.46×70.46

10
10
10
10
10
10
10
10
10

300
300
300
300
300
300
300
300
300

70.04 ×70.04×70.04
70.35×70.35×70.35
70.23×70.23×70.23
69.35×69.35×69.35

10
10
10
10

300
300
300
300

Table 3-5 Binding free energy components calculated with MM-PBSA for the wildtype and mutants of VQIVYK oligomer of tau
peptide (Sh2-St5)

Δ Eelec.

Wild type
Mean std
446.4724.29

Mutant -V1G
Mean std
396.4049.64

Mutant -I3G
Meanstd
379.3622.97

Mutant –Y5G
Meanstd
396.2939.45

Δ Evdw

-101.844.74

-85.054.29

-89.534.29

-80.014.47

Δ Egas

344.6224.30

311.3550.17

289.8322.37

316.2838.48

Δ GPB

-404.42 23.24

-359.2045.04

-331.3019.30

-370.8038.51

Δ Gsur

-15.650.34

-14.050.48

-14.780.43

-13.680.33

Δ Gpolar

42.057.58

37.2010.03

48.069.13

25.488.44

Δ Gnon-polar

-117.495.08

-99.14.77

-104.34.72

-93.694.80

Δ GTOT

-75.446.22

-61.91  9.29

-56.258.34

-68.207.04

Energy (Kcal/mol)

* Evdw, and Eelec are the van der Waals and electrostatic binding terms. ΔGPB and ΔGsur are the solvation energies of polar and nonpolar
residues, calculated by Amber 10 using the Generalized Born model. ΔGpolar and ΔGnon-polar are the sums of polar energy (ΔEelec+
ΔGPB) and non-polar energy components (ΔEvdw+ ΔGsur), respectively. ΔGTOT is the sum of ΔGpolar and ΔGnon-polar. ΔGTOT (the binding
free energy can also be obtained using the equation, ΔGTOT = ΔEGAS + ΔGPB + ΔGSUR.
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Table 3-6 Binding free energy components calculated with MM-PBSA for wildtype and mutants of MVGGVV1 oligomer of Abeta
peptide (Sh2-St6)
Energy (Kcal/mol)
Δ E elec.
Δ E vdw

Wild type
Mean std
-214.2016.40
-94.885.58

Mutant- M1G
Mean std
-200.0025.12
-74.936.31

Mutant -V2G
Mean std
-262.6730.24
-76.934.85

Mutant -V5G
Meanstd
-187.4021.12
-78.134.56

Mutant -V6G
Meanstd
-239.1729.63
-81.065.58

Δ E gas

-309.0915.72

-275.6224.88

-339.6128.93

-265.5320.19

-320.2329.43

Δ G PB

230.47 55.68

222.67 23.68

265.3426.56

199.0318.34

244.0428.33

Δ G sur

-14.970.45

-12.970.76

-13.200.47

-13.190.49

-13.650.63

Δ G polar

16.2752.64

21.988.22

2.668.03

11.636.42

4.877.37

Δ G non-polar

-109.856.03

-87.907.07

-90.135.32

-91.325.05

-94.706.21

Δ GTOT

-93.5853.51

-65.916.36

-87.476.04

-79.695.17

-89.837.18
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Table 3-7 Binding free energy calculated with MM-PBSA for the wildtype and mutants of MVGGVV2 of Abeta peptide (Sh2-St6)
Energy (Kcal/mol)
Δ E elec
Δ E vdw

Wild type
Mean std
-641.6738.91
-132.127.26

Mutant -M1G
Mean std
-419.66 37.36
-102.915.88

Mutant- V2G
Mean std
-592.7633.31
-98.906.73

Mutant -V5G
Meanstd
-527.91 54.10
-106.596.44

Δ E gas

-773.8035.40

-522.57 35.91

-691.6633.23

-634.50 54.88 -661.8624.16

Δ G PB

631.05 33.17

432.44 32.78

580.1527.02

530.1749.25

538.0522.21

Δ G sur

-22.81 0.32

-19.16 0.38

-19.830.63

-19.510.38

-20.520.36

Δ G polar

-10.62 10.21

12.789.91

-12.6110. 51

2.2610.51

-6.5010.27

Δ G non-polar

-154.937.58

-122.076.26

-1187.36

-126.106.82

-137.847.15

-109.297.85

-131.349.80

-123.849.09

-144.33 7.47

Δ GTOT

-165.56  7.57
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Mutant- V6G
Meanstd
-544.5426.74
-117.32 6.79

Table 3-8 Binding free energy components calculated with MM-PBSA for wildtype and mutants of LYQLEN of insulin (Sh2-St6)
Energy (Kcal/ mol)
Δ Eelec
Δ Evdw
Δ Egas
Δ GPB
Δ Gsur
Δ G polar
Δ G non-polar
Δ GTOT

Wild type
Mean std
298.7936.86
-105.154.97
193.6535.14
-280.31 32.94
-16.580.32
18.488.39
-121.735.29
-103.24 6.30

Mutant – Y2G
Meanstd
374.3530.91
-80.864.71
293.4930.22
-362.93 26.10
-14.110.48
11.418.26
-94.975.19
-83.567.25
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Mutant – Q3G
Meanstd
359.94 33.49
-87.775.63
272.16 33.19
-345.0933.94
-15.080.43
14.856.86
-102.856.06
-88.006.07

Mutant –L4 G
Meanstd
327.5036.68
-86.634.87
240.8736.64
-307.9933.68
-15.270.42
19.508.27
-101.905.29
-82.40 7.42

Mutant – N6G
Meanstd
304.0136.57
-91.685.30
212.3234.90
-289.8734.98
-15.360.48
14.147.59
-107.855.78
-92.916.26

A

B

C

Figure 3-1 Chemical structure of VQIVYK (A), MVGGVV (B) and LYQLEN (C)
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A

B

C

D

Figure 3-2 The atomic representation of the aggregates of VQIVYK (A), MVGGVV1 B),
MVGGVV2 (C) and LYQLEN (D)
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Figure 3-3 Time evolution of the RMSD of the wildtype and mutants of single sheet with
different number of strands:(A) tau oligomer (VQIVYK), (B) Abeta amyloid (MVGGVV1) and
(C) insulin amyloid (LYQLEN)
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Figure 3-4 Time evolution of the RMSD values of wildtype aggregates of two sheets with
different number of strands: tau oligomer VQIVYK (A), Abeta amyloid MVGGVV1 (B) , Abeta
amyloid MVGGVV2(C) and insulin amyloid LYQLEN (D)
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Figure 3-5 Time evolution of the RMSD of wildtype and mutants of (A) VQIVYK oligomer of
(Sh2-St6) tau peptide, (B) MVGGVV1 oligomer of (Sh2-St6) Abeta peptide, (C) MVGGVV2
oligomer (Sh2-St6) of Abeta petide and (D) LYQLEN oligomer of (Sh2-St6) insulin
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Figure 3-6 Time evolution of the secondary structure contents for Sh2-St5 aggregate of
VQIVYK and its mutants (A) Wild type, (B) Y5G, (C) I3G and (D) V1G
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Figure 3-7 Time evolution of the secondary structure contents for Sh2-St6 aggregates of
MVGGVV1 Wild type and mutants (A) Wild type, (B) V6G, (C) V5G, (D) V2G and (E) M1G
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Figure 3-8 Time evolution of the secondary structure contents for Sh2-St6 aggregate of
MVGGVV2 wild type and mutants (A) Wild type, (B) V6G, (C) V5G, (D) V2G and (E) M1G
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Figure 3-9 Time evolution of the secondary structure contents for Sh2-St6 aggregate of
LYQLEN wildtype and mutants. (A) Wildtype (B) N6G, (C) L4G, (D) Q3G and (E) Y2G
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Figure 3-10 Snapshots of Sh2-St5 aggregates of VQIVYK wild type and mutants at 5 ns (top) and 10ns (bottom). (A) Wild
type, (B) V1G, (C) I3G and (D) I5G. While the wild type is the most stable, the mutant I3G is the least stable.
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Figure 3-11 Snapshot of Sh2-St6 aggregate of MVGGVV1 and mutants at 5ns (top) and 10ns (bottom) (A) Wild type, (B)
M1G, (C) V2G, (D) V5G and (E) V6G. The wild type is the most stable, while the V6G and M1g mutants are the least stable.

89

5 ns, wildtype

5 ns, M1G

5 ns, V2G

5 ns, V5G

10 ns, wild type

10 ns, M1G

10 ns, V2G

10 ns, V5G

A

B

C

D

5 ns, V6G

10 ns, V6G
E

Figure 3-12 Snapshots of Sh2-St6 aggregates of MVGGVV2 and mutants at 5ns (top) and 10ns (bottom) (A) Wild type, (B)
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90

5 ns, wild type

5 ns, Y2G

5 ns, Q3G

5 ns, L4G

5 ns, N6G

10 ns, wild type

10 ns, Y2G

10 ns, Q3G

10 ns, L4G

10 ns, N6G

C

D

A

B

E

Figure 3-13 Snapshots of Sh2-St6 aggregate of LYQLEN and mutants at 5ns (top) and 10ns (bottom) (A) Wild type, (B) Y2G,
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CHAPTER 4
ALTERNATIVE PACKING MODES AS BASIS FOR
AMYLOID POLYMORPHISM IN FIVE FRAGMENTS

4.1

Background

X-ray diffraction of amyloid fibrils indicated the structure is highly conserved along the
fibril axis, with variation in the plane of the fibril cross-section.132 There are three major
structural features that may decide the overall amyloid fibril morphologies: (1) backbone
orientation; (2) backbone conformation; and (3) the way in which the oligomers associate. The
combination of these three factors can give rise to an enormous variation in conformational detail
and fibril morphology.133
Eisenberg laboratory was able to grow three-dimensional microcrystals 16,22,94,93,30,134 and
determine atomic resolution structures of about 50 short fibril-forming peptide segments of
hexapeptide abd hepatpetide fragments of several amyloid proteins (inclusing insulin, A, tau,
prion and amylin). These studies have identified examples for most out of eight possible packing
classes (parallel and antiparallel β-sheetsstacked face to face or face to back in parallel or
antiparallel manner). These common motifs called steric zippers, in which interdigitated side
chain hold together pair of β-sheets.22,18 Further, some peptides are capable of forming different
types of steric zipper, that offers a possible explanation for amyloid polymorphism.22
Polymorphism of amyloid fibrils by a range of proteins including Aβ, prion, glucagon and
amylin has been observed and is influenced by the environment in which the fibrillogenes
occurs. The polymorphic nature of Aβ peptide fibrils has been suggested to alter their pathogenic
action. Polymorphism of amyloid lead to difference in terms protofilament backbone regions,
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secondary structure, chromophore alignment along the fibril axis, and fibril superstructure.135
While the selection of the filament structure depends on the growth condition, which can be
purely mechanical agitation, once a stable filament is formed, it continues to grow, keeping the
atomistic order even if the growth condition changes.136 A fundamental question remains
regarding how these structures are formed. The importance of oligomer polymorphism is
increasingly recognized, explaining several observations, from propagation of prion strain
infectivity and other protein polymorphism 136, 137, 138, 139 to the variable cytotoxicity of amyloids
differently grown from the same peptides and proteins
and off-path intermediates of fibril growth

143, 142

139, 140, 141, 142

, the appearance of in-path

and the structural heterogeneity of amyloid

fibrils and their precursors grown from the same peptide/protein under different environmental
conditions.144, 145
Hydrogen-bonding interactions are inherent to -sheet stability.146 The stacking of
multiple β strands in amyloid fibrils has been, in part, ascribed to cooperative hydrogen
bonding.147 Molecular modeling has shown that polar residues β-sheets are stabilized by
hydrogen bonds between polar side chains, such as those between glutamine and asparagine. The
glutamine- and asparagine-rich regions are commonly found in the N-termini of both mammalian
and yeast prion proteins. Glutamine/asparagine (Q/N) rich domains show a greater tendency to
form self propagating amyloid fibrils. Gln and Asn rich sequence are prone to assemble into
different amyloid structures, since they are able to form diverse array of molecular interactions.
They can be donor or acceptor of both main-chain/side-chain and side-chain/main-chain
hydrogen bonds.148 Our previous study comparing the aggregation behaviors of short segments
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of amyloid peptides with small hydrophobic residues (VQIVYK, MVGGVV) and Q/N rich
residues (LYQLEN) indicated there is a greater stability in LYQLEN segment from insulin.78
The extra structural stability of the Q/N residues LYQLEN aggregates may be related to the
number of hydrogen bonds formed between the backbone and the side chains.149
The significant role of steric zipper in the structural stability of short amyloidogenic
peptides have been demonstrated by molecular dynamic studies.

88, 98,150

Park et al.

95

address

the structural selection mechanism of different double layer peptides including GNNQQNY,
NNQQ, VEALYL, KLVFFAE and STVIIE, and found that the patterns with the lowest binding
free energy correspond to X-Ray structures. Wu et al

151

using MD simulation in combination

with ssNMR data proposed two polymorphs of A9-40 peptide fibril. Papacone et al

152

presented

a systemic study between two polymorphic forms of A9-40 suggesting double layer morphology
is more stable than the three fold morphology. Computational investigation on the structure,
energy, and solvent interaction of four classes of A dodecamers by Ma et al 153 indicate that sheets packed orthogonally could be the most stable species for A dodecamers. Berryman et al
154, 101

investigated the thermodynamic stability of various possible polymorphic models of short

segments of amyloid peptides.
Here we report on multiple all-atomic MD simulations with explicit water at
300K,conducted on five polymorphic pairs short amyloidogenic peptides oligomers aggregates
in a crystal-free context. We performed the simulation starting with experimentally determined
microcrystal structure. Our study focuses on investigating the stability of various polymorphic
pairs. This study aims to answer the following questions:
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1)

What is the effect of side chain (polar versus nonpolar) on the stability of pair of steric

zipper polymorphs forms of small amyloid segments?
2)

Among the studied pair of polymorphs which one of them are more stable in crystal free

context under physiological conditions?
3)

Is there a relationship between hydrogen bond content and structural stability?

4)

What is the driving force for the association of the polymorph aggregates?

5)

How does a single point mutation of the N/Q side chains in the steric zipper of NNQNTF

and GNNQQNY influence the stability of the aggregates?

4.2

Methods

The polymorphic pairs of five small peptides (VQIVYK,

SSTNVG, MVGGVV,

GNNQQNY and NNQNTF) were investigated. The aggregates were derived from the crystal
structure with different packing polymorphs (Figure 4-1). The microcrystal structure and
coordinate of the five peptides polymorphic forms I and II (VQIVYK, SSTNVG, MVGGVV,
GNNQQNY and NNQNTF) assembled with two layers of β sheets was determined by Eisenberg
group.22, 93,16 The detailed summery of the simulation conditions of each the peptides and single
point mutation of N/Q residues with glycine in the steric zipper for are GNNQQNY and
NNQNTF are shown in Table 4-1. The microcrystal structure chosen in this study represent three
major groups: polar steric zipper rich with Q/N residues (GNNQQNY and NNQNTF), polar
steric zipper not rich in Q/N residues (SSTNVG and VQIVYK) and nonpolar steric zipper
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(MVGGVV). All of the studied structures were hexapeptide (except GNNQQNY, which consists
of seven residues).
The hexapeptide SSTNVG is a segment of amylin (residue 28-31) that forms fibrillar
amyloid deposits among the pancreatic β-islet cells of type II diabetes. Microcrystals of
SSTNVG grown from different solutions revealed two polymorphs. The SSTNVG form I
features a pair of serine residues at the center. The structure of SSTNVG form II packing has the
center of the interface Asn31, rather than Ser29 (Figure 4-1A).16 The hexapeptide VQIVYK,
residue 306-311 of the tau, forms intracellular amyloid fibrils in Alzheimer‟s disease.22 The
structural organization of VQIVYK is a parallel β-strand within the same β-sheet layer while
maintaining anti-parallel organization between the adjacent β-sheet layers.22 The VQIVYK from
tau protein shows polymorphism. The VQIVYK form I is characterized by an apolar dry
interface made essentially by the side chains of V1 and I3 of the two sheets and polar interface
involving Tyr and Gln side chains (Figure 4-1B). The VQIVYK form II is characterized by an
apolar dry interface made essentially by the side chains of V1 and I3 of the two sheets (Figure 41B).16 VQIVYK form I can be transformed to the VQIVYK form II by moving the top sheet to
the right. The hexameric peptide segment 170-175 from elk prion with amino acid sequence
NNQNTF forms two facial polymorphs. Both of them are found in the same crystal structure.
One of them is with a face to face packing, with N1, Q3 and T5 of both sheets forming the
interdigitated interface while the other one is a back to back, with side chains N2, N4 and F6
interdigitated (Figure 4-1C).16 The microcrystals formed from Aβ (35-40) peptide under different
incubation conditions gives two different crystal structures showing different conformations and
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arrangements of the peptides MVGGVV from Aβ protein. The MVGGVV peptide consists of
anti-parallel -strands within the same -sheet layers. The shape complementarity involves the
side chains of Met1, Val2, Val5 and Val6 -sheet. The MVGGVV form II polymorph is different
from the MVGGVV form I in that that there is 900 bending in the upper sheet of MVGGVV
form II (Figure 4-1D). The heptameric peptide with amino acid sequence GNNQQNY from the
yeast prion Sup35 forms two crystalline forms.30,22 The -strands are stacked parallel and are
oriented upwards within each -sheet, and the -sheets are face-to-face i.e. the same residues on
each -strand interdigitate. Both of them share many similarities. The polar side chains of the dry
interface (Asn 2, Gln 4, and Asn 6) are tightly interdigitated with the same three side chains of
the mating sheet (Figure 4-1E). These opposing side chains do not form hydrogen bonds with
each other; rather, their shapes complement each other closely, forming van der Waals
interactions. They also exhibit some differences, particularly around the tyrosine residue, which
appears to play a stabilizing role across sheets in the monoclinic form but not in the
orthorhombic form.30, 22
Computational mutation of the Q/N residues involved in the dry steric-zipper between the
sheets for NNQNTF and GNNQQNY was preformed to examine the effect of a single point
glycine mutation All the starting structures of the mutants were built from the wild type
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by

replacing the side chains of the targeted residues with glycine, but without changing the
backbone conformations of side-chain orientations using VMD.155 The simulation details for
each model are summarized in Tables 4-1.
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The trajectories obtained on the production stages were analyzed to examine the
structural change of the oligomers aggregates. The root mean square deviation (RMSD), root
mean square fluctuation, inter-sheet distance and inter-strand distance were calculated. To gain
an insight into the driving force for association of the preformed oligomer we used a molecular
mechanics/generalized Born-surface area method and normal mode analysis (NMA) to calculate
various energy terms in binding free energy (G) .156 We also examined the stability of the
oligomers by following the changes in the number of hydrogen bonds and their occupancy.

4.3

Result

4.3.1 Structural stability of wild type steric zipper packing polymorphs: RMSD and
RMSF analysis.
The conformational stabilities of the oligomers were monitored by the time evolution of
the backbone root mean square (RMSD) and root mean square fluctuation (RMSF) relative to
their initial energy minimized structure as shown in Table 4-2 and Figures 4-2. The RMSDs
provide useful information on relative stability of the oligomers, and were previously used in
stability analyses of amyloid oligomers with -sheet structure.21, 98, 157, 158
The RMSD values for the studied oligomers were calculated for backbone heavy atoms against
the corresponding energy minimized structures. To examine the effects of the polar versus
nonpolar side chain steric zipper on the stability of amyloid oligomers the mean RMSD
(<RMSD>) averaged over the five trajectories was determined. The <RMSD> for both nonpolar
and polar dry interface of the five polymorphs are shown in Table 4-2 and Figure 2. The
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<RMSD> of the polar Q/N oligomers (GNNQQNY and NNQNTF) were less than 2.0 Å
suggesting the Q/N rich peptides maintained the initial structure (see Figure 4-3). The heptapeptide GNNQQNY with one additional amino acids was found to be relatively more stable with
an <RMSD> less than 1 Å. The average RMSD for the other non Q/N rich systems was in the
range of 2 to 5.0 Å within the 20 ns simulations. The larger <RMSD> indicates the oligomers
that are not rich in Q/N residues are more flexible than those with Q/N side chain at the steric
zipper. The oligomers with largest <RMSD>, those with an RMSD  4 Å, were the two
polymorphic forms of MVGGVV and polymorph form II of VQIVYK. A closer look at the
structure of these three models indicates that they are having the smallest sheet-to-sheet
interface, consequently, their final solution conformations moves further away from the
conformation of the initial model (Figure 4-3). The qualitative structural stability comparison of
the oligomers based on RMSD of the may be used to predict which of the one of the polymorphs
pair might exist outside of the crystal environment.159 The RMSD during the 20 ns simulation for
the Q/N rich oligomer (NNQNTF and GNNQQNY) indicates both forms could exist with similar
probability under physiologic condition. Among the other three pairs it might be possible to find
the both polymorph form with similar probability for SSNTVG and MVGGVV. The polymorph
form I of VQIVYK based on the <RMSD> is most likely to be a dominate structure under
physiologic condition. A recent structure based design of amyloid aggregation for tau peptide
inhibitor used the VQIVYK polymorph form I as a template160 indicating the significant of the
determining the difference in stability of the packing polymorph of the steric zipper segments of
amyloid peptides.
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The residue-based root mean square fluctuations (RMSF) of the backbones were used to
assess the local dynamics and flexibility of each residue for the five polymorphic forms using
ptraj tool in AMBER11. Figure 4-2 shows the RMSF profiles of the different oligomers of the
wildtype of various studied amyloid oligomers. The RMSF values for all the five pairs of the
amyloid peptide models from our simulations indicates both N- and C-terminal regions residues
have a larger RMSF as they are exposed to the solvent water molecules with greater mobility.
The models GNNQQNY and NNQNTF have the smallest RMSF compared to other models (see
Table 4-2 and Figure 4-2). The RMSF values for the model VQIVYK-II, MVGGVV-I and
MVGGVV-II are generally larger than other models. The RMSF analysis is consistence with the
RMSD in that the structural stable Q/N rich oligomers have both smaller RMSF and RMSD
while the structurally unstable models (VQIVYK-II, MVGGVV-I and MVGGVV-II) have a
larger RMSD and RMSF.

4.3.2

Inter-strand (dstrand) and inter-sheet (dsheet) distances

To examine the structural stability of the wildtype of the five polymorphic forms
oligomers we analyzed the inter-strand and inter-sheet. The dstrand is calculated by averaging the
mass center distance between each residue in one strand and the respective in-register residue in
the adjacent strand, whereas dsheet is calculated by averaging the mass center distance between
sheets.75 The inter-sheet and inter-strand distances for wild type are shown in Table 4-2 and
Figures 4-4. The inter-strand and inter-sheet distance from the simulations for the Q/N rich
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models GNNQQNY and NNQNTF were found to be almost the same as the initial structures
(see Table 4-2 and Figure 4-4). These results indicate the GNNQQNY and NNQNTF models
have a greater structural stability (see Figure 4-3). The polar side chains of Asn and Gln with
larger sheet-to-sheet interface keeps together the two neighboring sheets. Significant changes in
inter-strand and inter-sheet distances were observed for the models with smaller sheet-to-sheet
interface for the nonpolar small size side chain at the steric zipper (VQIVYK and MVGGVV).
4.3.3

Sheet-to-sheet association energy

To further quantify the driving force underlying the β-sheet association of the studied
wildtype amyloid polymorph models, we calculated the interaction energy between β-sheets for
the three pairs (SSNTVG, NNQNTF and GNNQQNY) using the MM-PBSA module

80

in the

AMBER package. The VQIVYK and MVGGVV pairs showed a larger RMSD values with
significant conformational changes making it difficult to apply the MM-PBSA single trajectory
approach for calculating sheet to sheet association energy.80 The entropy calculation is and thus
the -T∆S was averaged over 100 frames of the MD trajectory (1 frame taken at an interval of 50
frames from the total of 5000 frames).
The non covalent association of the -sheets of amyloid aggregates takes place
spontaneous only if it is associated with a negative binding free energy.88 Detailed
characterization of individual energy terms of the calculated binding free energy are shown in
Table 4-3. The individual energy terms may be of similar or opposite in sign. An inspection of
the free energy components for the wild types investigated in this study reveals that the
electrostatic component of the solvation free energy ΔGPB is destabilizing (positive), while the
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nonpolar component GSA is stabilizing (negative). This is expected, since the complex formation
desolvates the monomers, and reduces solvent-accessible surface area. Entropy component was
found to contribute unfavorably to binding, since complexation reduces freedom of motion for
the monomers. The electrostatic interaction between sheets is stabilizing. These observations are
consistent with previous calculations of the components of the free energy of solvation.88
However, the less favorable electrostatics in each case is compensated by highly favorable
nonpolar component of the free energy. In each case, favorable nature of the nonpolar interaction
mostly originates from the van der Waals interaction energy ΔGvdW, as opposed to the nonpolar
component of solvation ΔGSA. Despite the fact that the -sheets association for the oligomers
(see Table 4-3) shows a more favorable binding enthalpy, there is an entropy penalty (-5.27 to 9.91). The order water molecules around the amino acid residues in the peptide upon the -sheets
association are released and to an increase in entropy.
In order to identify the residues that contribute the most to the calculated overall binding
energy, we used a residue-by-residue decomposition protocol. Binding free energy
decomposition at the atomic level allows evaluating the contribution of each residue to the total
binding free energy, as well as the contributions of its side-chain and backbone. The
MMPBSA.py script in AMBER11 implements per-residue decomposition with both PB and GB
implicit solvent models.54 The PB non-polar solvation component is currently not decomposable.
However, the non-polar solvation remains constant about -1.50Kcal/mol (see Table 4-3) and is
much smaller than the other energy terms. Thus, we used the MM-PBSA decomposition and the
results are show in Figure 4-5 to 4-7. The residues making the most favorable contributions to
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the binding free energy between the two sheets are the residues situated at the interface between
the two sheets and form stable hydrogen bonds between their backbone atoms and van der Waals
interactions between their side-chains (Figure 4-5 to 4-7). The contribution of the N/Q sidechains to the association of the 5 stranded double layer oligomers is larger than the other
nonpolar and small size amino acids at the interface, underlining the importance of Q/N amino
acid in stabilizing the short segment amyloid peptides in crystal free context.

4.3.4

Structural stability of the wildtype oligomers: hydrogen bond analysis

The amyloid configuration and properties primarily depend on the density of hydrogen
bonds involving the backbone of the polypeptides, while the side chains hydrogen bonds are
involved in the geometrical details and extension of the disordered parts of the structure.161,162
To further characterize the structural stability of the studied oligomer models we determined the
number of the hydrogen-bonds as the function of the MD simulation. The numbers of hydrogen
bonds in the GNNQQNY and NNQNTF systems are larger than the corresponding hydrogen in
the other remaining models (see Figure 4-8). The amyloid configuration and properties primarily
depend on the density of hydrogen bonds involving the backbone of the polypeptides, while the
side chains hydrogen bonds are involved in the geometrical details and extension of the
disordered parts of the structure.162 Figure 4-8 shows the number of hydrogen bonds throughout
the simulation for the various models studied. The results of the analysis of total, main chain and
side chain hydrogen bonds indicate the Q/N rich models content more hydrogen bonds. The
hydrogen bond analysis indicates the GNNQQNNY and NNQNTF are more stable with an
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average of 8 and 5.5 hydrogen bonds per strand. The remaining other models with hydrogen
bond of less than 3.5 are less stable. The hydrogen bond analysis in combination with the
geometric stability analysis (RMSF, RMSD etc.) were found to support that an increase in side
chain and main chain hydrogen bonds increase the stability of the short peptide oligomers.
We also performed statistical analysis on the number of hydrogen bonds to determine
their occupancy. Hydrogen bond occupancy is defined as ratio of times where the hydrogen bond
is present relative to the total time length of the considered trajectory. Hence, hydrogen bonds
that are never disrupted correspond to unit occupancy. Hydrogen bonds were characterized
according to their temporal occupancy during the 20 ns simulation using criteria based on angle
and distance. The strength of a hydrogen bond can be characterized by two geometric quantities
which govern the hydrogen bond energy: hydrogen bond angle, D–H · ·A atoms and optimal
hydrogen bond length, H · ·A (or D · ·A) distance 76. Hydrogen bond occupancies and structure
RMSDs was calculated using PTRAJ module available within AMBER. A hydrogen bond is
assigned if the distance between donor D and acceptor A is ≤3.5 Å and the angle D-H
…A≥120o.75 Those hydrogen bonds in the backbone with a fractional occupancy greater than
50% (considered to be strong hydrogen bonds) are detailed in Figure 4-9. The hydrogen bond
occupancy analysis revealed that a large value of average occupancy of hydrogen bonds is in
general associated with small average structural fluctuations and greater stability (see Figure 4-9
and Figure 4-3). The stability of the Q/N rich oligomers was found be supported by large values
of average hydrogen bond occupancy compare to the oligomer lacking Q/N amino acid side
chains. The MVGGVV segment pairs with antiparallel arrangement of strand per sheets lacks
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side chain hydrogen bonds. The absence of the side chain hydrogen bond, despite a similar
number of total hydrogen bond contents and occupancy as in the slightly stable SSNTV forms ,
might be the main reason for it instability. The highly stable Q/N rich models contents a greater
number of side chain hydrogen bond which responsible for retaining the initial microcystal
structure in crystalline free physiological environment.

4.3.5 Effect of mutation of Q/N residues at steric zipper on the stability of NNQNTF and
GNNQQNT
Side chain mutagenesis has proven to be a very effective means of identifying energetically
important backbone H-bonds and side chain interactions (including hydrophobic and electrostatic
interactions) in peptides.163 To test the hypothesis that the stability of the Q/N rich oligomers is
due to the presence of the extra side chain hydrogen bonding we did Gly-mutations of the Q and
N side chains involved in the steric zipper for GNNQQNY and NNQNTF wildtype oligomers
with Hydrogen (performed in silico mutations) The summary of the structural stability of the
mutants are shown in Table 4-2. The simulation revealed that mutation of the Q and N residues
at the steric zipper for the GNNQQNY oligomer affect the structural stability. In the case of
mutants Q4G and N6G after the 20 ns simulation one of the -strands starts to separate from the
remaining aggregates (see Figure 4-10). The mutation of Asn-2, Gln-4, or Asn-6 by Gly could
disrupt the steric zipper, leading to unstable oligomers. The hydrogen bond analysis showed the
mutants had a smaller backbone-backbone and side chain-side chain hydrogen bonds compared
to the wildtype. The simulation of the NNQNTF mutants (N1G and Q3G) showed mutant Q4G
is having a larger RMSD, RMSF and smaller hydrogen bond contents with significant structural
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instability compared to the wildtype (Table2 and Figure 4-10). The mutation of the polar Asn
and Gln side chains at the steric zipper with Gly revealed the polar side chains of Asn and Gln
are important for the stability the oligomers of GNNQQNY and NNQNTF.

4.4

Conclusions

The major findings of our 20 ns multiple MD simulation suggests the following
qualitative conclusions:
1.

The short segments amyloid peptide rich in Q/N amino acid are have greater structural

and the packing polymorphs are stable and under crystal free contents and physiological
environments they might have similar probability of occurrence.
2.

The short segments amyloid peptide lacking the Q/N amino acid have been found to be

structurally unstable and the packing polymorphs show different stability with greater chance
different probability of occurrence under crystal free contents and physiological environments.
3.

The simulations of Q/NG mutants disrupted the steric zipper, leading to unstable

oligomers. The comparison of the structural stability of the wildtype and mutants stability of the
Q/N rich oligomers was found be supported by large values of average hydrogen bond
occupancy of the wild type compare to mutants.
4.

The Q/N residue rich short amyloid segments have larger hydrogen bond contents and

hydrogen bond occupancy. The overall increase of hydrogen bond in the Q/N residue rich
peptides with smaller RMSD, RMSF and greater stability suggesting the stability of oligomer
models is associated with an increase in side chain and total hydrogen bond contents.
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5.

The MM-PBSA binding free energy method was applied to the study of the -sheet

association. The nonpolar component of free energy is more favorable, while the electrostatic
solvation is unfavorable for sheet to sheet interaction. The decomposition of the binding energy
per residue showed the contribution of the N/Q side-chains to the association of the 5 stranded
double layer oligomers is larger than the other nonpolar and small size amino acids at the
interface, underlining the importance of Q/N amino acid in stabilizing the short segment amyloid
peptides in crystal free context.
Our simulations provide detailed insight into the structural stability of various short
segment amyloid oligomer aggregates Exploring the structural stability and aggregation behavior
of the short peptides may gain insights into the self-assembly process at the early stage of fibril
formation and provide a clue to structure based design of amyloid aggregation inhibitors. The
rational design of successful therapeutic strategies requires detailed characterization of amyloid
formation. Polymorphism in amyloid peptides with the same sequence is due to difference in βsheet packing (steric zipper).22 Landau et al

16

found that different aggregation inhibitor

molecules bind to different polymorphs of amyloid peptides and suggested a combination of
aggregation inhibitors might be required to bind to the various morphologic form of a given
amyloid peptide. Sievers et al

164

using known atomic structures of segments of amyloid fibrils

as templates have designed amyloid aggregation inhibitors. Our simulations indicate that there is
a difference in the stability polymorphs of a given sequence and certain amino acids are
significantly important for stability. Results from this work might be useful in designing
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peptidomimetic aggregation inhibitors by single amino acid change or shuffling the sequence so
as to disrupt the steric zipper and prevent amyloid aggregation.
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Table 4-1 Summary of simulation system and condition of double layer models of amyloid peptide segments with packing
polymorphism
Model name
SSTNVG 1 (SH2-ST5)
SSTNVG 2 (SH2-ST5)
VQIVYK 1 (SH2-ST5)
VQIVYK 2 (SH2-ST5)
NNQNTF 1 (SH2-ST5)
N1G (SH2-ST5)
Q3G(SH2-ST5)
NNQNTF 2 (SH2-ST5)
GNNQQNY 1 (SH2-ST5)
N2G(SH2-ST5)
Q4G(SH2-ST5)
N6G(SH2-ST5)
GNNQQNY 2 (SH2-ST5)
MVGGVV 1 (SH2-ST5)
MVGGVV 2 (SH2-ST5)

Sheet organization
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/parallel
Parallel/antiparallel
Parallel/antiparallel

# peptide/
water mol.
760/2633
760/2689
1140/4575
1140/3890
960/2967
890/3006
860/3021
960/3482
1070/3284
1000/3351
970/3397
1000/3340
1070/3241
820/4200
820/3785

PDB
code
3DG1
3FTR
2ON9
3FQP
3FVA
3FVA
1YJP
2OMM
2ONA
2OKZ
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Length (ns)
simulation
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20

Simulation box size (Å)
58.01×58.01×58.01
58.41×58.41×58.41
69.00×69.00×69.00
65.88×65.88×65.88
60.50×60.50×60.50
60.64×60.64×60.64
60.74×60.74×60.74
63.35×63.35×63.35
62.42×62.42×62.42
62.88×62.88×62.88
63.09×63.09×63.09
62.76×62.76×62.76
62.25×62.25×62.25
67.13×67.13×67.13
64.98×64.98×64.98

T., K
300
300
300
300
300
300
300
300
300
300
300
300
300
300
300

Number of
simulation
5
5
5
5
5
1
1
5
5
1
1
1
5
5
5

Table 4-2 Summary of structural analysis of double layer amyloid peptide segments with packing polymorphism
Model name

<RMSD>

<RMSF>

SSNTVG-I
SSNTVG-II
VQIVYK-I
VQIVYK-II
NNQNTF-I
N1G
Q3G
NNQNTF-II
GNNQQNY-I
N2G
Q4G
N6G
GNNQQNY-II
MVGGVV-I
MVGGVV-II

3.52(1.22)
3.53(0.46)
2.45(0.55)
5.49(1.12)
1.73(0.45)
1.78(0.41)
2.39(0.53)
2.06(1.43)
0.93(0.07)
0.84(0.19)
2.52(0.77)
1.77(0.21)
0.86(0.05)
4.06(0.94)
4.49(0.95)

1.76(0.52)
1.64(0.36)
1.34(0.2)
1.99(0.22)
0.79(0.09)
0.78(0.50)
0.80(0.58)
0.85(0.28)
0.55(0.03)
0.55(0.41)
1.41(0.97)
0.79(0.57)
0.53(0.02)
2.09(0.34)
2.13(0.25)

Simulation (Å)
<dsheet>
<dstrand >
7.75(1.04)
10.06(0.22)
13.64(0.5)
15.61(2.65)
8.85(0.19)
7.85(0.29)
6.83(0.18)
10.97(0.37)
9.74(0.04)
8.62(0.14)
8.74(0.55)
8.91(0.23)
9.66(0.06)
8.53(0.89)
8.86(0.86)

6.33(1.01)
5.69(0.37)
5.57(0.27)
5.81(0.16)
5.18(0.08)
5.17(0.13)
5.08(0.20)
5.08(0.08)
4.96(0.01)
6.98(0.09)
5.35(0.22)
5.48(0.240
4.93(0.01)
5.36(0.29)
5.53(0.26)

Crystal (Ås)
<dsheet>* <dstrand>‡
6.22
4.79
8.96
4.79

*

11.03
9.16
8.50
8.50
8.50
10.52
9.61
8.50
8.50
8.50
10.04
7.50
8.01

4.86
4.86
4.84
4.84
4.84
4.84
4.87
4.84
4.84
4.84
4.93
4.84
4.76

Average number of hydrogen bonds
<Total H-bond> Main-chain Side-chain
24.70(1.21) 16.84(0.88)
39.09(1.92)
21.35(1.38) 13.15(1.21)
36.68(0.85)
29.67(1.43) 4.7(0.77)
35.41(1.81)
26.79(1.11) 3.59(1.11)
30.54(1)
24.63(0.90) 29.34(3.25)
58.41(2.11)
26.9(1.93) 20.86(2.87)
49.22(4.08)
20.53(2.38) 18.48(2.34)
37.49(4.23)
25.90(1.60) 13.19(1.10)
51.95(0.52)
29.38(0.68) 48.80(1.46)
79.93(0.94)
31.06(0.98) 41.64(2.70)
73.48(2.89)
20.46(3.79) 13.01(3.64)
37.49(4.23)
29.21(1.42) 37.57(2.45)
68.71(2.94)
21.45(0.67) 51.11(1.60)
76.43(0.86)
33.14 (2.7)
32.27(1.94)
0.7(0.40)
32.07(2.65)
0.6(0.41)
33.17(2.94)

The inter-sheet distance (dsheet) was calculated by averaging pair-wise residue Cα-Cα distances between the adjacent β-sheet as the shortest distance
between two the main chain atoms of two opposing strands in the dry interface: (SSNTVG-I: S-N,S-T,T-S and N-S; SSNTVG-II: S-V,T-N, N-T and V-S;
VQIVYK-I: V-Y, I-I and Y-V, VQIVYK-II : V-I and I-V; NNQNTF-I and NNQNTF-II:N-F, N-T ,Q-N , N-Q, T-N , and F-N; GNNQQNY-I and
GNNQQNY-II: G-Y, N-N, N-Q , Q-Q , Q-N, N-N and Y-G; MVGGVV-I: V-G,G-V and G-M , and; MVGGVV-II: ,G-M,V-G , and G-V)
‡
Angular brackets < > indicate time averaging and the mean values and standard deviation (SD) were calculated by using the five trajectories for each
models. Mutations were done using the initial structure of the on the most stable polymorphic forms and the analysis was done on a single trajectory
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Table 4-3 Summary of the MM-PBSA components of the double layer amyloid peptide segments with packing polymorphism
Contribution
<∆Evdw>
<∆Eele>
<∆GPB>
<∆GSA>
<∆Gsolv>
<∆Gsubtotal>
<-T∆S>
<∆G(per stand)>

Model name
SSNTVG-I
-14.83(1.80)
-228.34(17.87)
230.13(16.81
-1.40(0.10)
228.73(16.72)
-14.44(2.33)
-9.16(0.58)
-5.27(1.77)

SSNTVG-II
-14.14(0.65)
-209.97(13.82)
210.46(12.04)
-1.39(0.07)
209.06(12.08)
-15.05(2.06)
-9.28(0.50)
-5.77(1.77)

NNQNTF-I
-23.58(0.53)
-187.71(2.91)
193.04(4.80)
-1.95(0.05)
191.08(4.76)
-20.204(1.89)
-10.29(0.48)
-9.91(2.14)

NNQNTF-II
-19.76(0.42)
-97.40(4.50)
104.50(4.59)
-1.53(0.04)
102.97(4.55)
-14.19(0.37)
-7.52(0.28)
-6.68(0.48)

GNNQQNY-I
-20.54(0.13)
-174.86(1.98)
178.55(2.24)
-1.56(0.01)
176.99(2.24)
-18.41(0.18)
-8.97(0.32)
-9.44(0.31)

GNNQQNY-II
-20.62(0.05)
-176.04(1.18)
179.95(1.34)
-1.57(0.01)
178.38(1.13)
-18.28(0.10)
-9.12(0.13)
-9.16(0.06)

Binding free energy components (kcal mol−1) and standard deviations calculated with MM-PBSA for oligomer double-layers
(SH2-ST5 ) models: Average over 5000 snapshots of the trajectory. b Entropy calculations were based on normal modes analysis using
100 snapshots (1 frame taken at an interval of 50 frams from the total of 5000 frames). Δ Evdw, non-bonded van der Waals energy;
ΔEele, non-solvent electrostatic potential energy; ΔGPB, electrostatic contributions to the solvation free energy calculated with PoissonBoltzmann equation; ∆GSA , ∆GSolv are nonpolar and total solvation energies; -TΔS; Entropic contributions to binding. ΔS; sum of
rotational, translational and vibrational entropies; ΔG (per stand), per strand binding energy of the system. All energies are in kcal/mol.
ΔGsubtotal = ΔEvdw + ΔEele + ΔGsol; ΔGsol = ΔGPB + ΔGSA; ΔEgas = ΔEelect + ΔEvdW and ∆G(per stand)= ΔGsubtotal-TΔS
*
Mean values were calculated by using the five trajectories for each model from the multiple simulations. Standard deviation
(SD) was also calculated by using the five trajectories.
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A

B

SSTNVG form I

SSTNVG form II

VQIVYK form I

C

VQIVYK form I

D
MVVGGVV form I

MVVGGVV form II

NNQNTF form I

NNQNTF form II

E
GNNQQNY form I

GNNQQNY form I

Figure 4-1 Structure of polymorphism of steric zippers of amyloid peptide segments studied (A) SSTNVG from IAPP, (B) VQIVYK
from tau protein, (C) NNQNTF from elk prion, ) GNNQQNY form yeast prion Sup35 and (D) MVGGVV from Abeta.
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Figure 4-2 RMSD and RMSF values as a function of time. The RMSD and RMSF were calculated by averaging over five trajectories
compared to the starting structure in each models. (A) RMSD for polymorph form I, (B) RMSD for polymorph form II, (C) RMSF for
polymorph form I and (D) RMSF for polymorph form II. The RMSF values are average for 10 -strands.
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SSNTVG form I

NNQNTF form I

NNQNTF form II
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SSNTVG form II

VQIVYK form I
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MVGGVV form I

MVGGVV form II

Figure 4-3 Superposition of the backbone atoms of the staring conformation with the conformation at 20 ns. The initial structures are
colored in blue while the structure after 20 ns simulation is shown in red. The structure for the conformation after 20 ns was taken
from the trajectory with the smallest RMSD and RMSF values out of the five trajectories for each system.
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Figure 4-4 The averaged inter-strand distances (A and B) and inter-sheet distances (C and D) calculated by averaging over five
trajectories. The distances were measured in comparison with the corresponding initial structure in each model.
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Figure 4-5 MM-PBSA per residue decomposition of total binding free energy. (A) SSNTVG
polymorph form I and II , (B) NNQNTF polymorph form I and II and (C) GNNQQNY
polymorph form I and II.
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Figure 4-6 MM-PBSA per residue decomposition of side chain contribution to binding free
energy. (A) SSNTVG polymorph form I and II , (B) NNQNTF polymorph form I and II and (C)
GNNQQNY polymorph form I and II.
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Figure 4-7 MM-PBSA per residue decomposition of backbone contribution to binding free
energy. (A) SSNTVG polymorph form I and II , (B) NNQNTF polymorph form I and II and (C)
GNNQQNY polymorph form I and II.
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Figure 4-8 Comparison of the number of H-bonds as a function of MD simulation, for five pairs
of polymorphic packing of amyloid oligomers: SSTNVG, VQIVYK, MVGGVV, NNQNTF and
GNNQQNY. The hydrogen bonds were determined with respect to the energy minimized
structures.
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Figure 4-9 The hydrogen bond occupancy for the side-chain–side-chain and main-chain–sidechain atoms throughout the simulations. The cut off used for H-bond distance and angle for each
system was 3.5 Å and 1200. The average occupancy of the main chain and side chain hydrogen
bonds were calculated by using five trajectories. The average is over the entire simulation
trajectories. Hydrogen bonds with occupancy  50% are considered here
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GNNQQNY mutants:

NNQNTF mutants:

N2G

Q4G

N1G

N6G

Q3N

Figure 4-10 Superposition of the backbone atoms of the staring conformation of the Q/N rich mutants with the conformation at 20 ns.
The initial structures are colored in blue while the structure after 20 ns simulation is shown in red. The structure for the conformation
after 20 ns was taken from the trajectory with the smallest RMSD and RMSF values out of the five trajectories for each system.
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CHAPTER 5
CONTROLLING THE AGGREGATION AND RATE OF
RELEASE IN ORDER TO IMPROVE THE INSULIN FORMULATION

Chapter 5, in part, is a reprint of the material as it appears in Journal of Molecular Modeling,
2011, Workalemahu M. Berhanu  Artem E. Masunov, Published online: 15 June 2011; DOI
10.1007/s00894-011-1123-3

5.1

Background

Insulin is a 51-residue protein hormone consisting of two polypeptide chains: the chain A
(comprising 21 residues) and the chain B (comprising 30 residues), linked together by three
disulfide bonds (Figure 5-1A). Insulin is stored in the body in the secretory vesicles of the
pancreas as a zinc-containing hexamer. When in the blood stream, insulin is present in its
biologically active monomeric form.165,166 The underproduction of insulin or lack of receptor
sensitivity to insulin is known to cause diabetes that is affecting 171 million people
worldwide.167 Insulin is the mainstay of drug therapy for patients with type I diabetes, and can
reduce the morbidity in the long term. The disease is caused by autoimmune destruction of
insulin secreting  cells of the pancreas. Without sufficient levels of insulin, these patients
cannot properly utilize glucose and typically have markedly elevated blood glucose
(hyperglycemia) while intracellular glucose levels are generally low. The chronic complications
of a consistently high blood sugar level are serious and include retinopathy (diabetes is the most
common cause of blindness), neuropathy, nephropathy (diabetes is a leading cause of chronic
renal failure), cardiovascular disease, peripheral vascular disease (diabetes is the leading cause of
limb amputation) and makes the patient more susceptible to infection.168
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Similar to many other proteins, insulin can misfold and form highly ordered fibrillar
amyloid aggregates. Insulin fibrils have been observed in vivo following continuous
subcutaneous insulin infusion

169

and repeated insulin injections

170

; they are the main factor in

the pathogenesis called injection amyloidosis.2,17 These insulin fibrils that form in vivo display
the defining characteristics of amyloid aggregates associated with neurodegenerative diseases 111
including binding to the dye Congo red with “apple-green” birefringence, they show an
elongated, unbranched fibrillar morphology17, they exhibit nucleation-dependent polymerization,
and they present a cross-β X-ray diffraction pattern.2 Recently, serum samples from patients with
Parkinson‟s disease have been found to display an autoimmune response to insulin oligomers
and fibrils

110

, possibly indicating the presence of insulin aggregates in this disease too. Insulin

also forms amyloid-like fibrils in vitro, which are promoted by elevated temperatures, low pH,
and increased ionic strength.112,111 In addition, insulin fibril formation has been a limiting factor
in long-term storage of insulin for treatment of diabetes. Amyloid fibrillation may cause
problems during both production, storage and drug delivery of protein based pharmaceuticals.94,6
In the case of commercial insulin, fibril formation is a problem in some of the isolation and
purification steps, when

pH is lowered 1-3.111 The agitation of insulin solutions during

transportation and in portable delivery systems may also induce fibrillar aggregation.171,94,6
Moreover, in therapeutic use of protein drugs, it is essential to avoid the fibril formation, since
amyloid fibrillated protein is biologically inactive 111,172 and may cause immunological responses
in patients.172,173 Future drug development may be aim to either stabilize native structure, inhibit
the formation of crucial intermediates on the pathway of fibril formation, or to prevent
interaction between fibrillation intermediates such as the partially unfolded monomer and
oligomers.6,111 Modifications of the amino acid sequence of insulin, such as single point
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mutations, influence both insulin activity and protein aggregation.174 The newer insulin
analogues have several improvements due to their modified action profile.175 Main advantages of
short-acting preparations include faster onset of action and shorter duration time. Long-acting
analogues afford structural changes that delay the onset of action, allow slow and continuous
absorption into the systemic circulation, and prolong the duration, thus producing a timeconcentration profile that imitates the normal insulin basal level and leads to physiological basal
glycaemic control with less nocturnal hypoglycaemias.176
Upon aggregation, the molecule of insulin undergoes structural changes from a
predominantly -helical state to a β-sheet rich conformation, and many models of insulin fibrils
have been suggested6,111,177 repeatedly. The segment B11-B17 with sequence LVEALYL is the
smallest segment that can both nucleate and inhibit the fibrillation of full-length insulin,
depending on the molar ratio. This fact is suggesting that this segment is central to the cross-beta
spine of the insulin fibril.94 In addition, the point mutations H10D and L17Q in the chain B of
insulin prolong the lag phase of insulin fibrillation, further supporting the importance of this
segment in fibril formation.178 Also, exposing this fibril-prone segment by truncating the five
residues of the chain B C-terminal increases the propensity of insulin for fibril formation.179
Recent studies have shown that the chain A also contributes to insulin fibrillation. Both
chain A and chain B can form fibrils on their own

108,109

and seeds of these chains can nucleate

the fibrillation of full length insulin.108 In addition, it was reported that segments as short as six
residues from either chain A (residues A13–A18) or chain B (residues B12–B17) can form fibrils
by themselves.180
The first atomic-resolution view of the fibrillar spine came from single crystal structures
of the segments LYQLEN (residues A13–A18) and VEALYL (residues B12–B17).22 The
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combination of several complementary techniques (including X-ray diffraction of insulin fibrils
and scanning-transmission electron microscopy analysis of the morphology of insulin fibrils)
allowed

a

highly reliable

structure

of

full-length

insulin

amyloid

fibrils

to

be

constructed.94,181,182,183 This model has a β-solenoid structure consisting of repeated structural
units of similar but not identical peptides, covalently connected by 2 disulfide bonds.

94,183

The

solenoids are linked by a dry steric zipper formed by the mating of the central two LVEALYL
(residues B11-B17) strands. Because LYQLENY contains a Tyr residue in the second position,
this side chain superimposes on a Tyr from LVEALYL preserving the „„kissing tyrosine‟‟
interaction observed across the wet interface of the crystal of LVEALYL (Figure 5.1).
Computational studies have complemented experiment to provide insights into insulin
aggregation. All-atom molecular dynamics (MD) simulations have been applied to study the
amyloid oligomer stability by testing different candidate β-sheet arrangements of preformed
oligomers mimicking possible nucleus seeds at the very early stage of fibril formation.21,184,185
Mark et al.186 performed series of shorter molecular dynamics simulations to investigate the
structure of monomeric and dimeric insulin in aqueous solution. Their simulation showed that in
the absence of crystal contacts both monomeric and dimeric insulin have a high degrees of
intrinsic flexibility in the absence of crystal contacts. Monomer MD simulations187,188 established
that the proposed binding site for glucose is stable, both statically and dynamically.189 Other MD
simulations of the insulin dimer (but not monomer) have been published.190,191 They reveal
details concerning the dynamics of the dimer during the simulation, including the hydrogen bond
pattern and correlated motions.
In this study, we report on an MD study of the single layer insulin aggregates based on
the high resolution models of insulin fibril with the purpose of understanding the nature of
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insulin self-assembly. We present the information on energetics of the insulin association at an
atomistic level that could be used to design new short- and long- acting insulin analogues.
Mutant forms of insulin with altered aggregation properties that could potentially be used to in
slow- or fast- acting therapeutic formulations are suggested on the basis of the observed contacts
at the aggregates interface. There has been no pervious systemic study on how mutation affects
the stability of the insulin oligomer aggregates. Our MD simulations of the different size of the
insulin oligomer may contribute to a better understanding of the nucleation process and
conformation change at the very early stage of fibril formation. This study aims to answer the
following questions:
1.

Which regions of the wild-type insulin oligiomer aggregate are flexible?

2.

How do the single point mutations influence the structure and flexibility of these regions?

3.

What are the effects of single glycine mutations of the side chains involved in the steric

zipper?
4.

What are the conformational differences among the aggregates of various sizes?

5.2

Methods

We conducted a total of ~0.35μs of explicit-solvent molecular dynamics (MD) simulation
on the insulin single layer insulin aggregate oligomer and mutated sequences with intact
disulfide bridges, using temperatures 330 K to emulate the experimental conditions of in vitro
insulin fibrillization.66,67
In this study we rely on insulin fibrillar model constructed by Ivanova et al

94

using crystal

structure of the LVEALYLV, SLYQLENY and fiber diffraction patterns. The C-terminal region
of chain B (residues 20–30) is not involved in amyloid fibrillization
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183

, and was omitted.

Comparison of amino acid sequence of the insulin sequences from five different mammalian
species (porcine, bovine, sheep, mouse and rate) in the residue 20-30 shows nine of the amino
acids residues are conserved and B30 Tyr in human is replaced with Ala in the other species.176
These residues are missing in the insulin model used in this study. Therefore, only the 40 amino
acids are taken into account in the fibrils model.94 The starting coordinates (Figure 5-1) for the
MD simulations was taken from the amyloid fibril home page of David Eisenberg group
available at: (http://people.mbi.ucla.edu/sawaya/jmol/fibrilmodels).
Ten different single point glycine mutant simulations were conducted to examine the
effects of steric zipper. In chain A the following three single point glycine mutations were done:
a) tyrosine (Y) in position 14 replaced with glycine (G), b) leucine (L) in position 16 replaced
with glycine (G), c) asparagines (N) in position 18 replaced with glycine (G). While in chain B a
total of seven mutations were done: d) leucine (L) in position 11 replaced with glycine (G), e)
valine (V) in position 12 replaced with glycine (G), f) glutamic acid (E) on position 13, replaced
with glycine(G), g) alanine (A) in position 14 replaced with glycine (G), h) leucine (L) in
position 15 replaced with glycine (G), i) tyrosine (Y) in position 16 replaced with glycine (G), j)
leucine (L) in position 16 replaced with glycine (G). The three mutants in chain A will be
termed: Y14GA, L16GA and N18GA. The other seven mutants in chain B will be termed: L11GB,
V12GB, E13GB, A14GB, L15GB, Y16GB and L17GB, respectively. All the starting structures of
the mutants were built from the wild type
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by replacing the side chains of the targeted residues

with glycine, using VMD.155 Such analogues may possibly allow increasing the potency of
insulin-based medicines, extending the time of action and controlling it using prodrugs, as well
as enhancing the bioavailability. Insulin analogues were developed to try and achieve more
physiological insulin replacement from injection in the subcutaneous site.
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The insulin single layer oligomer aggregates studied contains multiple protein-protein
interfaces; the calculation of the free energy of the associations of monomers in single layer
oligomer aggregates requires a suitable interface. Because the present study aimed to assess the
stability of the insulin oligomer with respect to the increase in the number of strand (the
longitudinal growth) and the effect of mutation of amino acids involved in intra-chain, we
measured the interaction energy between the edge (B) chains and the central double layer (A) as
shown in Figure 5-2. A molecular mechanics–Generalized Born surface area (MM-GBSA)
method was used to calculate the binding free energies in the insulin single layer complex. The
free energy analysis was done using a single trajectory approach.

5.3
5.3.1

Results

Relative structure stability of insulin oligomers

The conformational change and the conservation of the oligomers were monitored by the
time evolution of the backbone root mean square (RMSD) and root mean square fluctuation
(RMSF). The RMSDs provide useful information on relative stability of the oligomers, and were
previously used in stability analyses of amyloid oligomers with -sheet structure.21,78,86,157,158 In
Figure 5-3 we plot RMSD of the wild type and mutants oligomer aggregates relative to the
corresponding initial structure as a function of simulation time.
The conformation change and conservation of oligomers stability of the different size
wild type insulin oligomer was monitored by the time evaluation of the RMSD. In Figure 5-3, we
plot the RMSD of the insulin oligomers of the main-chain heavy atoms relative to the
corresponding initial structure as a function of simulation time. The profiles of RMSD deviation
appear to reach reasonable plateaus during the 10 ns production run, indicating that statistical
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convergence has been attained in these simulations. The average main-chain RMSD between the
MD simulation and the initial structure were found in the range of 4.3 to 4.9 Å for WT and 3.75
to 4.75 Å for the mutants. Along the trajectories the systems tend to keep the original
conformation. In the case of the wildtype monomer and dimer a large conformational flexibility
is observed as indicated by the RMSD, RMSF (Figure 5-3 and 5-4), average secondary structure
content (Table 5-1) and cluster analysis (Figure 5-6). The RMSF and cluster analysis presented
in Figure 5-3 and Figure 5-6 for the monomer indicates it undergoes larger conformational
changes forming a globular structure instead of the initial solenoid form. The C-terminus of the
monomer bends to the central region, and forms an anti-parallel β-sheet between residues 12-16
and residues 35-40. The dimer largely preserves the solenoid conformation, but exhibits larger
per residue fluctuation values in the beta sheet region in chains A (11SLYQLENY19) and B
(12VEALYL17), that are twice as large as the RMSF in other cases (Figure 5-4).
The residue-based root mean square fluctuation (RMSF) of the backbones was used to
assess the local dynamics and flexibility of each residue using ptraj tool in AMBER11. Detailed
analysis of RMSF of the Cα, C, N atoms versus the residue number for insulin wild type and
mutants oligomer aggregates is shown in Figure 5-4. The large size oligomer such as SH1-ST8
and SH1-ST10 are more flexible at their N- and C-termini as compared to its smaller size
oligomers (except SH1-ST2). The relatively larger RMSF per residue of the SH1-ST1 and SH1ST2 is found the β-sheet region indicates their instability and the loss of the initial fibril
conformation (Figure 5-4A). The other oligomers (SH1-ST4 to SH1-ST10) the β-sheet region
exhibits significantly smaller structural fluctuation from the fibril conformation. Figure 5-4B and
C shows the RMSF values of atomic positions by each residue, computed throughout the
simulation for wildtype of insulin (SH1-ST10) and corresponding single point glycine mutants.
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The RMSF of single point mutants were found to be larger than the wildtype. The smallest
fluctuation of the average RMSF in for chain A and chain B was found in the segments
LYQLENY and LVEALYL respectively. The RMSF results for the wildtype and the mutants
indicates that all chains have common characteristics of small variation in the residue located
within the β-sheet region whereas large variations for residues in the termini regions. The larger
flexibility of the two termini residues were due to the reduction of hydrogen bonds between the
peptides. The side chains of the termini residues are more exposed to the water and tend to form
hydrogen bonds with water molecules.88

5.3.2

Secondary structure content

We carried out secondary structure analysis using DSSP tool in AMBER11. Table 5-1
reports the average number of residues in a given secondary structure as a function of simulation
time and the corresponding initial structure. When the average secondary structure content over
time is considered differences between smaller oligomers and larger size oligomer are evident
from the simulations. The single and double stranded aggregates exhibits lower -sheets and
more residues in helices and in coil-like conformation. The larger oligomers (such as SH1-ST4
to SH1-ST10) exhibit exhibits more -sheets contents and fewer residues in helices and in coillike conformation. The larger aggregates retain the fibril conformation mainly due to an
increased number of backbone hydrogen bonds.88

5.3.3

Cluster Analysis

Cluster analysis or in short clustering puts similar samples of data into groups called
clusters, such that an ensemble of data, for example, the different structures obtained from a MD
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trajectory, is partitioned into groups of similar objects. Structural clustering is useful to
understand the molecular motion within conformational space.192 Conventional clustering
algorithms are reducing any large MD trajectory to a set of conformational basins. To identify
the most populated conformations sampled, clustering of all snapshots from the trajectories was
performed using the ptraj program of AMBER11. The standard approach, which has been used
with considerable success, is to cluster the configurations in terms of an RMSD. For clustering,
we utilized the average linkage algorithm implemented in ptraj.77 The uniqueness or equivalence
of different clusters was assessed based on visual comparison of representative structures. The
clustering was performed on a 5000-frame reference set (4 ps sampling rate). Figure 5-6 shows
the superposition of the initial structure and the most populated cluster structure for single-layer
insulin aggregates of different sizes. The analysis of the structures indicated the most populated
clusters detected from the smaller size oligomers (single and double strand) indicating larger
structural rearrangements compared to the initial conformation taken from the fibril model. The
conformation was preserved for larger aggregate (SH1-ST8 and SH1-ST10).

5.3.4

Free energy calculation

Detailed characterization of individual energy terms of the calculated binding free energy
of the studied insulin oligomer aggregates are shown in Table 5-2. An inspection of the free
energy components for the wild types and mutants reveals that the electrostatic component of the
free energy of binding (ΔEele) contributes unfavorably to binding (ΔG > 0). The nonpolar
component contributes favorably (ΔG < 0) as expected, since formation of complexes reduces
solvent-accessible surface area. In most cases the electrostatic component of the solvation free
energy ΔGGS is consistently favorable. The interaction energy due to electrostatic interaction
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(ΔEvdw) between strands led to unfavorable binding. These observations are consistent with
previous calculations of the electrostatic component of the free energy of solvation. However,
the less favorable electrostatics in each case is compensated by highly favorable nonpolar
component of the free energy. In each case, favorable nature of the nonpolar interaction mostly
originates from nonpolar component of solvation (ΔGGB) and the van der Waals interaction
energy (ΔEvdw).
The result of the binding free energy calculation (Table 5-2) indicates the structurally
stable models have the lowest binding free energy, while the models which are structurally
unstable were found to have the largest binding free energy. The difference in binding free
energy between the wild-type and mutated complex is defined as:
Δ∆Gmut = ΔGmut-ΔGwild

(1)

A positive and negative Δ∆Gmut values indicate the unfavorable and favorable contributions. The
positive Gmut values of 37.3 to 1.4 kcal/mol of the mutants in the -sheet region (except
Y14GA and L15GB) indicate their lower tendency to aggregation compared to the wildtype. This
result from our simulation could be used in rational design new insulin analogues with decreased
propensity for self-association avoiding injection amyloidosis of insulin. The relatively larger
positive value of Δ∆Gmut for mutants (Y14GA, L11GB, V12GB and E12GB) indicates the less
favorable association compared to the wildtype. In general substitution of -sheet region of chain
A and B by a small, short Gly disrupts the steric zipper shape complementary and weakens
hydrophobic interactions (see Table 5-2).The single point glycine mutation reduces the
unfavorable electrostatic interaction. The mutation of the negatively charged glutamate (E) to G
in the mutant E12GB reduces the electrostatic repulsion in the wildtype as is evidence in the
significant reduction of the unfavorable electrostatic interaction (Table 5-2). Mutation of Tyr14
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in chain A with glycine eliminates the hydrogen bond between the residues Tyr14 of chain and
the Tyr16 of chain B as the result the calculated binding free energy was high. The negative
value of value of Δ∆Gmut for a mutant is due to the increased hydrophobic interaction in the
steric zipper between the chains. Complete hydrophobic side chain by Gly substation impedes
fibril growth.193 The trend in the calculated binding free energy is in agreement with the
observed instability based on RMSD, RMSF. Those aggregate oligomer models which show
structural instability were found to have unfavorable binding energy compared to the stable once.

5.3.5

Decomposition free energy on a per-residue basis

The free energy decomposition not only identifies the binding energy hot spots, but also
gives insight into the nature of the key interactions.189 To provide the basic information on the
intermolecular interactions contributed from the individual residues in the insulin single layer
aggregate interaction decomposition of free energy (the per residue total, side chain and
backbone binding free energy) was evaluated using the decomposition energy module in
AMBER11. The calculation was performed over the 2500 MD snapshots taken from the 20 ns
simulation. The summations of per residue interaction free energies were separated into the
residue backbone (G backbone bind) and the side chain (G side chain bind). The energy
contributions from the selected residues are summarized in Figure 5-5.
The result form the energy decomposition shows the major contribution to the binding energy of
insulin oligomer aggregate is gained from the key amino acid residues (those with a Gbinding 0.50 kcal/mol) occurring mainly in the -sheet region. These residues are in chain A (Q5, L13,
Y14, Q15, L16, N18 and Y19) and in chain B (S9, L11, V12, L15, L17 and V18).The result of
the per residue decomposition indicates the important of the particular residues in the -sheet
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region with regards to the formation and stabilization of insulin and this is in agreement with
experimental observation.94 To establish the interaction associated with these residues, their
electrostatic, van der Waals and solvation energy terms are shown in Table 5-3 . Table 5-3 shows
that favorable contributions to the binding free energy arising from these residues relates to Eele,
Evdw, ∆GGS, while unfavorable comes from ∆GGB. The favorable Eele terms from the residue in
the β-sheet region are compensated by highly unfavorable repulsion from three glutamate
between adjacent insulin layers.

5.3.6

Fibril nucleation and the structure of insulin oligomers

Understanding the process of amyloid fibril formation is an important goal of protein
aggregation studies.47 Amyloids grow in a nucleation-dependent manner.35,47 Fibrillation kinetics
is typically characterized by an initial apparent lag phase related to the formation of oligomers,
protofibrils, and aggregation nuclei.194 The typical fibril formation process is characterized by a
lag phase in which no detectable fibers are formed. This is then followed by an elongation phase
in which fiber is formed over a time period often shorter than the lag phase. Eventually, the
process reaches equilibrium when most soluble proteins are converted into fibrils.195 On the other
hand, if fibers (oligomers, protofibrils, and fibrils) are already formed they grow extremely fast
with very short lag-times. A recent experimental work on oligomers capability to stabilize fibril
nucleation activity by Ono et al.196 on Aβ amyloid, on amylin
197, 198, 199,200

195

, and on insulin in various labs

have indicated the oligomers and the fibril showed different capability to act as

seeds. Anselm et al

184

used the degree of structural similarity to the fibril conformation detected

for the oligomers in their simulation as an possible reason for difference among various size of
oligomer with respect to the effective as nucleation seeds. The degree of structural similarity
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between fibril conformation and the conformation of the oligomers after MD simulation could be
used in explaining the shorting of the lag phase in the present of different size of oligomers. The
trend in retaining the initial fibril conformation will help us in getting an atomic level
explanation to the observed difference in the seed effects of various sizes of oligomers. The
results from our simulation show the single layer insulin oligomer as small as the trimer is
capable of preserving the conformation present in the fibril (See Figure 5-6). The dimer shares
some properties of the mature fibril. The monomer adopts a structure that differs significantly
from that of the fibril.
The secondary structure content and clustering analysis on the trajectories from the
various size single layer insulin oligomer shows the larger aggregates retain the fibril
conformation and the smaller ones (SH1-ST1 and SH1-ST2) lose this conformation. The
observation could be used to explain the shortening of the nucleation lag phase of insulin
aggregation with oligomer seeds. Insulin like other amyloid peptides follow an apparent
nucleation-dependent polymerization kinetics47,201 whereby a small number of monomers
associate through a free energy barrier corresponding to a critical nucleus size, beyond which
initiates gradient of favorable free energy or “down-hill” polymerization. Based on the result of
the secondary structure and cluster analysis we proposed the SH1-ST4 to be a critical nucleus for
the single insulin fibril oligomer growth. To characterize the critical nucleation we computed the
association energy different between our proposed minimum nuclei and the larger size oligomers
(SH1-ST6, SH1-ST8 and SH1-ST10) we using the equation.
∆∆G(n)= G(n)- (G4); n=4,6,8,10

(2)

The results are shown in Table 5-2. Our calculation shows that, for a high number of strands, the
oligomer is stable and its free energy is favorable for the addition of the new chains. The result
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of our semi-quantative approaches for insulin single layers of limited size of insulin single layer
are in agreement with those obtained from pervious extensive simulations done on Aβ amyloid
critical nucleus and mechanism of fibril elongation.202,203

5.4

Conclusions

The results from this work provided valuable insight into the forces that drive the stability
of the peptide-peptide complexes of the single layer aggregate oligomer models of insulin and
those that lead to unstable complexes. The study of the wild type and mutants in an explicit
solvent will provide valuable to future efforts aimed at the design of short –and long-acting
insulin analogs. The major findings of this study can be summarized as follows:
1.

The stability of the insulin single layer peptides oligomers increases as the number the

number of strands increases (dynamic cooperative effect) .
2.

The binding energy calculated by MM-GBSA method shows the hydrophobic

interactions play an important role in stabilizing the structural organizations of the single layer
insulin. Per residue decomposition shows the key amino acid residues (those with a Gbinding 1.00 kcal/mol) occur mainly in the -sheet region of both chain A and chain B. Due to the
electrostatic repulsion between the three negatively charged glutamates in adjacent insulin
strands, electrostatic repulsion to the binding energy is unfavorable.
3.

A single glycine substitution at the steric zipper interface disrupts the hydrophobic

contacts and reduces the van der Waals interactions in the mutants thus reducing the binding free
energy. The result of the binding free energy calculation indicated that the wild type is more
structurally stable than most of the mutants. A comparison of the binding free energy between
the wildtype and the chain A mutants (Y14GA, L16GA and N18GA) indicates shape
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complementarity between neighboring strands plays a key role to stabilize the entire oligomeric
structure.
4.

The secondary structure contents and clustering analysis of the trajectories of the single

layer insulin oligomers shows the larger aggregates retain the fibril conformation but the smaller
once (SH1-ST1 and SH1-ST2) lose this conformation. This observation could explain the
observed shortening of the nucleation lag phase of insulin aggregation with oligomer seeds.
Based on the result of the secondary structure and cluster analysis we proposed the SH1-ST4 is a
critical nucleus for the single-layer insulin fibril oligomer growth.
Our simulations provide detailed insights into understanding the structural stability and
aggregation behavior of the insulin single layer aggregates (obtained from a high resolution
insulin fibril model) at atomic level. In the search for clinically advantageous fast acting insulin
analogs several approaches were found to be useful for altering the monomer/monomer interface.
One of them is disruption of β-sheet interactions in the β-chain through charge repulsion, or
changes in hydrophobic interactions in the C-terminus of chain B

176

. Our simulations on the

wildtype and single glycine mutants at the steric zipper region show other parts of insulin
molecule can be targeted in the design of both short and long action insulin analogs as well.
Aside from the design of such insulin analogs, the present study may prove useful for rational
design of insulin aggregation inhibitors which could be used in stabilizing insulin formulations,
leading to their safer handling and more cost-effective storage especially in developing countries.
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Table 5-1 Average secondary structure contents of different size insulin wildtype and its (SH1-ST10) single point glycine mutants
Starting
Average
WT (SH1-ST2)
β-Sheet
β-Bridge
coil
turn
-Helix
310-Helix
-Helix

0(0)
23(63.9)
0(0)
2(5.5)
11(30.6)
0(0)
0(0)

β-Sheet
β-Bridge
coil
turn
-Helix
310-Helix
-Helix

0(0)
135(71)
0(0)
28(14.7)
16(8.4)
9(4.7)
2(1)

β-Sheet
β-Bridge
coil
turn
-Helix
310-Helix
-Helix

0(0)
133(72.3)
0(0)
39(21.2)
10(5.4)
0(0)
2(1.1)

0(0)
15.3(56.1),[3.6]
0(0)
6.4(23.5),[2.4]
3.9(14.3), [2.9]
1.6(5.9),[2.0]
0.05(0.2),[0.1]

L11GB (SH1-ST10)
0(0)
127.7,(68.3),[7.9]
0(0)
31.5(16.8),[4.9]
16.5(8.8), [4.9]
8.8,(4.7),[4.7]
2.5,(1.4),[2.2]

Y16G (SH1-ST10)
0(0)
127.7,(68.3),[6.0]
0(0)
31.5(16.8),[4.9]
16.5(8.8), [4.9]
8.8,(4.7),[4.7]
2.5,(1.4),[2.2]

Starting
Average
WT (SH1-ST4)
0(0)
47(63.5)
0(0)
9(12.2)
14(18.9)
2(2.7)
2(2.7)

0(0),[0]
42.3(62.3),[3.1]
0(0),[0]
10.3(15.2),[3.4]
12.1(17.8),[4.6]
2.7(4.0). [2.8]
0.5(0.7), [1.2]

V12GB(SH1-ST10)
0(0)
146(72.3)
0(0)
36(17.8)
9(4.5)
6(3.0)
5(2.5)

0(0),[0]
128,(68.8),[6.4]
0(0),[0]
37.6,(20.2),[5.0]
11.5,(6.2),[4.6]
8.4, (4.5). [4.3]
0.5(0.3), [1.3]

L17GA (SH1-ST10)
0(0)
146(72.6)
0(0)
23(11.4)
24(12)
3(1.5)
5(2.5)

0(0),[0]
135.1,(71.5),[6.7]
0(0),[0]
30.6,(16.2),[5.4]
17.9,(9.5),[5.2]
3.1, (1.6). [2.8]
2.5(1.2), [2.2]

Starting
Average
WT (SH1-ST6)
0(0)
83(68)
0(0)
25(20.5)
8(6.6)
6(4.9)
0(0)

0(0),[0]
69.9(79.6), [5.2]
0(0),[0]
16.4,(18.7).[4]
14.4,(8.7),[5.9]
8.4,(9.6), [3.9]
1.3,(1.5), [1.9]

E13GB (SH1-ST10)
0(0)
131(68.6)
0(0)
45(23.6)
4(2.1)
9(4.7)
4(2.1)

0(0),[0]
130.5(69.6), [7.9]
0(0),[0]
34.9,(18.6).[5.7]
12.6,(6.7),[5.3]
9.5,(5.1), [4.2]
0.3,(0.2), [1.0]

Y14GA (SH1-ST10)
0(0)
143(69.1)
0(0)
29(14)
24(11.6)
6(2.9)
5(2.4)

0(0),[0]
121.1,(66.0),[7.9]
0(0),[0]
30.0,(16.4).[5.9]
21.0(11.4),[7.6]
10.2,(5.6),[5.6]
1.2,(0.6),[2.0]

Starting
Average
WT (SH1-ST8)
0(0)
115(68.1)
0(0)
35(20.7)
12(7.1)
7(4.1)
0(0)

A14GB (SH1-ST10)
0(0)
134(69.1)
0(0)
46(23.7)
8(4.1)
6(3.1)
0(0)

0(0),[0]
120.9(69.2), [7.7]
0(0),[0]
38.8,(21.6).[5.2]
7.0,(3.9),[3.6]
9.8,(5.4), [4.1]
1.4,(0.8), [2.4]

L16GA (SH1-ST10)
0(0)
139(67.8)
0(0)
38(18.5)
13(6.3)
3(1.5)
12(5.8)

*Percentages and standard deviations are given in parenthesis and square brackets, respectively
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0(0),[0]
114(69.2), [5.7]
0(0),[0]
28.1,(17.1).[6.1]
14.4,(8.7),[5.9]
5.7(3.5), [4.1]
2.4(1.5), [2.7]

0(0)
127.8,(65.8),[6.8]
0(0)
39.0,(20.1),[5.8]
16.3,(8.4), [5.1]
9.8,(5.0),[4.5]
1.2,(0.6),[2.0]

Starting
Average
WT (SH1-ST10)
0(0)
158(73.8)
0(0)
45(21)
8(3.7)
3(1.4)
0(0)

0(0),[0]
135.6,(70.1),[7.6]
0(0),[0]
28.1,(17.1).[6.1]
11.2(5.8),[4.3]
11.8,(6.1),[4.6]
0.5(0.3),[1.0]

L15GB (SH1-ST10)
0(0)
157(70.7)
0(0)
40(18)
18(8.1)
7(3.2)
0(0)

0(0),[0]
142.5,(70.2),[7.6]
0(0),[0]
32.6,(16.1).[6.7]
17.5,(8.6),[6.2]
8.2,(4.0),[4.5]
2.3,(1.1),[3.0]

N18GA (SH1-ST10)
0(0)
151(70.9)
0(0)
36(16.9)
10(4.7)
9(4.2)
7(3.3)

0(0),[0]
122.9,(68.7),[8.2]
0(0),[0]
36.4,(20.4),[4.4]
7.3,(4.1),[5.6]
9.0, (5.0). [4.1]
3.2, (3.2), [2.4]

Table 5-2 Individual energy components of the binding free energy of insulin amyloid aggregate peptide
MM-GBSA binding energy components of the different size of the single layer insulin amyloid aggregates
∆Evdw
∆Eele
∆GGS
∆Gsolv
∆Gtotal
System
∆GGB
Δ∆G(6-n)
11.43
-163.960.18
576.651.02
-502.400.95
-21.350.02
-523.750.95 -111.060.17
WT(SH1-ST4)
0.0
-177.210.28
1149.660.91
-1071.500.86
-23.430.03
-1094.940.86
-122.490.24
WT(SH1-ST6)
-19.8
-149.640.19
1514.622.27
-1433.422.22
-25.810.02
-1459.272.22 -142.290.22
WT(SH1-ST8)
-13.79
-196.310.14
1827.75
-1742.521.00
-25.200.02
-1767.280.13 -136.280.13
WT(SH1-ST10)
MM-GBSA binding energy components of single layer insulin amyloid aggregates mutant of chain A (SH1-ST10)
System
∆Evdw
∆Eele
∆GGB
∆GGS
∆Gsolv
∆Gtotal
Δ∆Gmut
37.3
-165.160.12
1974.310.84
-1887.760.84
-20.360.02
-1908.110.84
-98.96016
Y14GA (chain A)
-16.59
-208.140.14
1710.421.74
-1628.031.73
-27.100.03
-1655.151.73 -152.870.16
L16GA (chain A)
-201.2720.12
1623.990.93
-1527.810.91
-26.020.01
-1553.820.91
-131.110.15
N18GA (chain A)
5.17
MM-GBSA binding energy components of single layer insulin amyloid aggregates mutant of chain B (SH1-ST10)
∆GGS
System
∆Evdw
∆Eele
∆GGB
∆Gsolv
∆Gtotal
Δ∆Gmut
19.2
1598.83.4
-1522.23.4
-22.00.02
-1544.23.4
-117.10.2
L11GB (chain B)
-171.70.23
-21.50.01
-1737.21.0
V12GB (chain B)
21.9
-167.10.2
1789.91.1
-1715.791.0
-114.40.2
E13GB (chain B)
12.1
-186.70.3
981.41.0
-893. 71.0
-25.30.02
-918.91.06
-124.20.25
7.1
-1533.34.0
-25.40.03
-1558.74.0
-129.20.25
A14GB (chain B)
-191.20.2
1620.84.0
-1555.62.4
L15GB (chain B)
-5.7
-209.30.2
1622.92.4
-15292.4
-26.60.02
-142.03
-1686.41.9
Y16GB (chain B)
7.6
-194.80.2
1752.61.9
-1663.11.9
-23.30.03
-128.6220.2
-1754.432.3
L17GB (chain B)
1.4
-204.40.3
1823.92.3
-1728.422.2
-26.00.02
-134.9040.2
Evdw and Eelec are the van deer waals and electrostatic binding terms, ∆GGB, ∆GGS, ∆Gsolv are the polar, non polar and total solvation
energies. Data are shown as meanSD. Standard error of the mean ∆Gtotal = ∆Evdw,+ ∆Eele + ∆Gsol , ∆Gsol = ∆GGB + ∆GGS, ΔGmut = ∆GmutGwild, the change of mutant binding free energy as to wildtype. Δ∆G(n-6) = Oligomer free energies expressed relative to the hexamer state for β-sheet oligomers.
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B
Figure 5-1 Amino acid sequence and structure of single-layer insulin oligomer (A) Amino acid
sequence of insulin (chain B top and chain A bottom). Segments LVEAYLV of chain B and
SLYQLENT of chain A are colored in green. Disulfide bonds are colored in blue. The Cterminal region of chain B underlined and in italic, is not involved in amyloid fibrillization. The
residues underlined are missing in the insulin model used in this study. Therefore, only the 40
amino acids are taken into account in the fibrils model. (B) Single -layered structural models of
insulin oligomers (10 stranded). Two chains are associated together via interdigitated pair of
LYQLENY molecules of chain A and LVEALYL molecules of chain B which interlock tightly
to form the dry steric zipper. The chain A is red and the chain B is blue. Disulfide bonds are
indicated in the yellow.
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A

B

C

Figure 5-2 Schematic drawing of the setup used for estimating the internal stability of insulin
single layer aggregates and mutants. Free energies of interaction were calculated between the
middle chains A (cyan) and the remaining edge chains B(red) reflecting the strength by which
chain A clamps the insulin stack in the β-solenoid structure.
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Figure 5-3 Backbone RMSDs of single layered insulin models and single glycine mutants (SH1ST10)
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Figure 5-4 Plot of the root mean square fluctuation (RMSF) of single layered insulin models and
single point glycine mutants (SH1-ST10)
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CHAPTER 6
THE ATOMIC LEVEL INTERACTION OF
POLYPHENOLS WITH THE OLIGOMER AGGREGATE OF VQIVYK
SEGMENT FROM TAU PEPTIDE

6.1

Background

The presence in tissues of amyloid plaques consisting mainly of amyloid fibrils arising
from the polymerization of specific peptides/proteins is a key hallmark of several degenerative
conditions including Alzheimer's, Parkinson's and type II diabetes.137 In Alzheimer's disease, the
tau peptide forms intracellular amyloid in the form of paired helical filaments (PHF).204,205 The
tau protein consisting of 441 residues binds and stabilizes microtubules.204 The tau peptides
aggregate via cross- hydrogen bonding, where two monomer -sheet structures adhere
together.205 The most important amino acid sequence in the tau peptide is

306

VQIVYK,311 as this

sequence has been shown to be necessary for amyloid formation through the cross-
interactions.205 The hexapeptide VQIVYK by itself forms insoluble -sheet aggregates
spontaneously in aqueous solution.

22

The VQIVYK segment of tau was suggested as the

minimal interaction motif for fiber formation.205 Landau et al 206 recently determined the atomic
structures of VQIVYK segment from the tau in complex with small molecule binders,
determined by X-ray micro-crystallography. The fiber-like complexes consist of pairs of βsheets, with small molecules binding between the sheets, roughly parallel to the fiber axis.206
Landau et al

206

proposed that the tube-like cavity along the β-sheets provides an adequate site

for the binding various aromatic compounds, such as polyphenols.207
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Amyloid fibrils exhibit a common molecular architecture in which arrays of β-strands are
connected by hydrogen bonds oriented parallel to the fiber long axis, into an array known as a
cross-β structure. The substructure of mature fibrils consists of one or more protofilament units,
which can assemble laterally or intertwine in various ways as rope-like or ribbon-like
modifications to the common fibrillar framework. 2 The finding that amyloid fibrils are stabilized
primarily by hydrogen bonds involving the polypeptide main chain explains why fibrils formed
from polypeptides of different sequence are morphologically and structurally similar.208
Presently, prefibrillar aggregates of different proteins and peptides are considered the most toxic
amyloid species, whereas mature fibrils are substantially devoid of cytotoxicity.137 Accordingly,
intra-cellular or extracellular prefibrillar aggregates are considered the main factors for cell
impairment and tissue degeneration in amyloid diseases.209,210 Therefore, agents that interfere
with early oligomerization are expected to be especially valuable for use in the therapy or
prevention of amyloid diseases. The toxic effects of amyloid aggregates to exposed cells,
includes nonspecific membrane permeabilization, oxidative stress, mitochondria impairment and
eventually apoptosis.211,212 A lot of many efforts are presently spent to find out naturally
occurring molecules, including polyphenols, or to design synthetic ones, that are capable to
protect cells against oxidative stress or the inhibition of the amyloid formation at its earliest
stages and disruption of the fibrillar structures.42,212 At present, there are no approved therapies
that target amyloid formation directly, but many organic molecules have been shown to inhibit
fibrillation in vitro, and thus represent an increasing list of proposed antiamyloid lead
compounds. Natural polyphenolic compounds from foods and traditional herbal medicines,
having broad pharmacological activities and exhibiting inhibition of amyloid formation, have
164

been extensively investigated in the disruption of mature amyloid fibrils and reduction of the
toxicity of fibrils to living cells.213,

214, 215,216

Recent publications

217, 218, 219

, have studied the

antiamyloid effects of natural polyphenols on three consecutive processes: formation of nascent
fibrils, elongation or extension of the fibrils, and destabilization of the formed mature
assemblies. The destabilizing effects include disaggregation/fragmentation of the fibrils and
conversion of the fibrils into amorphous deposition.220 Although many attempts have been made
to elucidate the molecular mechanism of natural polyphenols against amyloidogenesis, the
structure-activity relationship is still obscure and remains to be further explored.
Recent in vitro evidence has suggested that polyphenolic compounds (flavonoids) from
food products such as red wine and green tea have been reported to show antiamyloid activity.
221 222, 223, 219

Despite progress in experimental observations, there are still many questions about

amylin-resveratrol or amylin polyphenol interactions on a molecular level. For example, 1) What
are the physicochemical factors controlling polyphenol binding? 2) What are the molecular
interactions between polyphenols and the VQIVYK oligomers? 3) Does the polyphenols binding
induce changes the VQIVYK oligomers structure? 4) Are there difference in binding affinity
among the different polyphenols? Answering these questions will be important to our
understanding of the mechanism of VQIVYK oligomer fibril dissociation induced by polyphenol
and may aid in designing new antiaggregation agents. Many compounds have been reported to
show antiamyloid activity in various in vitro and in vivo experiments. Detailed structural studies
of the mechanism of action of already available antiamyloids can help in future development and
characterization of druggable modalities. All-atom computer simulations, such as molecular
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dynamics (MD), are well suited to provide molecular-level details of VQIVYK oligomer –
polyphenol interactions.
There have been several theoretical attempts to study the interactions between current
inhibitors and oligomers at the atomic level. Using all-atom molecular dynamics simulations
with explicit solvation model, Wu et al.

100

have identified and characterized two specific

binding modes of Congo red molecules to protofibrils formed by GNNQQNY. Binding of the
fluorescence dye thioflavin T (ThT) to the fibrils formed by Aβ fragments, Aβ16–22, has been
probed using all-atom MD.224 Two ThT binding sites were identified, one in the hydrophobic
groove on the fibril side and another on the fibril edge. From MD simulations, the binding
energetics for ThT was also computed. More recently, binding of tricyclic planar ligands (9, 10anthraquinone and anthracene) to fibril forming Aβ fragments (Aβ14–20) was investigated using
MD.225 The results showed that 9, 10-anthraquinone interferes with the formation of inter-strand
hydrogen bonds and reduces the accumulation of ordered aggregates. Dmitri and coworkers 226, 87
using replica exchange molecular dynamics and atomistic implicit solvent model, studied the
mechanisms of binding of naproxen and ibuprofen to the A beta fibril. Liu et al. 227 investigated
the molecular mechanism of the inhibition effect of trehalose on Aβ16–22 and Aβ40 peptides
with MD in explicit solvent. Neil et al

228

using molecular dynamics simulations compared the

mode of interaction of an active (LPFFD) and inactive (LHFFD) β-sheet breaker peptide with an
Aβ fibril structure. They found that LHFFD had a weaker interaction with the fibril than the
active peptide, LPFFD, from geometric and energetic considerations. 228 Recently we performed
an implicit solvent molecular simulations of amyloidogenic peptides (GNNQNNY) co-incubated
with polyphenols to probe the interaction between the ligand the amyloid aggregate models
166

86

.

Lemkul et al

229

using multiple dynamic simulations found the flavoniod morin can bind to the

ends of the fibrils blocking the attachment of an incoming peptide, penetrate into the
hydrophobic core to disrupt the Asp23−Lys28 salt bridges. They found combination of
hydrophobicity, aromaticity, and hydrogen bonding capacity of morin as a main factor
destabilizing the Aβ42 protofibril. Various labs reported that polyphenols physically disrupt tau
aggregates.230,231,232,233 It is this information that motivates this study. Clearly, there is great
interest in understanding how small molecules might interact with, and ultimately destabilize,
amyloid assemblies.
Polyphenolic compounds are attractive therapeutic candidates, as they are found in
natural food products, are capable of crossing the blood−brain barrier, and are nontoxic in
clinically relevant doses.234,235 Studies of the interaction of polyphenols such as epigallocatechin
236

and resveratrol

237

with α-synuclein and Aβ lead to the proposal, based in part on seeding

studies, that polyphenols functions as amyloid aggregation inhibitor by diverting polypeptides
from their normal amyloid formation pathway into nonproductive off-pathway states.
Polyphenols are characterized by the presence of several phenolic hydroxyl groups with acidic
property and with their planar structures their planar structure forms hydrogen bonds with
peptides.238
The VQIVYK segment of tau was suggested as the critical for tau polymerization.
Therefore, the tau peptide segment (VQIVYK) has been used as a simplified model system to
facilitate the discovery of key factors underlying amyloid fibril formation and the development
of antiamyloid agents. The structure of the hexapeptide with an amino acid sequence VQIVYK
(Residues 306-311) from tau protein in complex with small molecules has been recently been
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determined by Landau et al.206 The atomic structures of small molecules bound to amyloid reveal
the molecular framework of small-molecule binding, within cylindrical cavities running along
the -spines of the fibers. These complexes reveal a molecular framework which partially
defines the amyloid pharmacophore, the structural features responsible for the binding of small
molecules to amyloid aggregates.
MD studies of polyphenols binding to VQIVYK oligomer of tau peptide to the best of
our knowledge have not been performed. We used MD simulations with explicit-solvent to study
the interaction of curcumin, myricetin and exifone with a preformed oligomers aggregate of
VQIVYK from tau peptide. Detailed binding free energies between curcumin, exifone and
myricetin and individual protein residues of the oligomers of VQIVYK were computed by using
a per-residue basis decomposition method, which provides insights into the inhibitor-protein
binding mechanism and also explains the mechanisms of the aggregation inhibitor effect of
polyphenols.

6.2

Methods

The structure of the oligomer aggregate of the hexapeptide with an amino acid sequence
VQIVYK (Residues 306-311) from tau protein in complex with small inhibitor molecules has
been recently been determined by Landau et al
bound

the

polyphenol

206

curcumin,

The X-ray structure of VQIVYK oligomer
taken

from

the

web

page

http://people.mbi.ucla.edu/meytal/CoCrystalPaper/#V6K-CUR, served as the starting point for

modeling VQIVYK complex with myricetin and exifone. The myricetin and exifone were
docked

to

the

peptide

fibrillar

structure
168

using

Sirius

graphics

program

(http://www.ngbw.org/sirius/) The schematic representation for the strcutureof the polyphenols
is shown in Figure 6-1. The molecular dynamic (MD) simulation was performed using
AMBER11 packcage

63

with an all atom amber99SB force field and explicit TIP3P water

models. Each of the VQIVYK oligomer models with and without the polyphenols were solvated
by explicit water molecules that extends 10 Å from any edge of the octahedral box to the protein
atoms. Table 6-1 shows a summary of the simulations. Each system was simulated for 20 ns and
the trajectories were saved at 8.0 ps intervals for further analysis. A hydrogen bond was assigned
if the distance between donor D and acceptor A is  3.5 Å and the angle D-H …A  1200 239.
Structural analysis was performed using the PTRAJ module of the AMBER 1163 software
package. VMD (visual molecular dynamics)
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program was used for the visualization of

trajectories. The MM-PBSA single trajectory approach implemented as script (MMPBSA.py) in
Amber11, was used to calculate the binding energy. Solute entropic contributions were not
calculated in this study since they are only crudely estimated by normal mode analysis. Although
the MM-GBSA(MM-PBSA) calculations may overestimate the absolute binding free energy due
to the missing terms (e.g., conformational entropy change of the solute upon binding) and
underestimate the desolvation free energy, they usually give a reasonable qualitative estimate on
the relative binding free energy when two similar ligands are compared.80,240

6.3

Results

To examine the structural stability of the VQIVYK oligomers with and without
curcumin, exifone and myricetin we analyzed, the Cα root-mean-square deviation (RMSD)
versus time, the Cα root-mean-square fluctuation (RMSF) as a function of the residue number,
169

twist angle and hydrogen-bonding pattern. All the reported quantities have been computed over
the 20 ns of the production simulations of each system. The conformational stabilities of the
VQIVYK oligomers with and without the ligands were monitored by the time evolution of the
backbone root mean square (RMSD) and root mean square fluctuation (RMSF) relative to their
initial energy minimized structure as shown in Table 6-2 and Figures 6-2. The RMSDs and
RMSF provide useful information on relative stability of the oligomers, and were previously
used in stability analyses of short amyloid oligomers with -sheet structure.86, 241, 149 To compare
the effect of polyphenols binding to the VQIVYK oligomer we calculated the RMSD of C of
the apo form and in complex with the ligand of the oligomer as shown in Figure 6-2A. The
overall structure of the aggregates of the VQIVYK segment of tau peptide in complex with the
polyphenol ligands is changing as is evidence by larger (2.0 Å) deviation in C of the complex
compared to the negative control aggregate model. The lowest deviation from the starting
structure is detected for VQIVYK when bound to exifone. The highest rms deviations for
VQIVYK oligiomer was observed when the oligomer is bound to curcumin. Root mean square
fluctuation(in Å) from the initial structure of the VQIVYK-backbone atoms over the time course
of the molecular dynamics simulation when bound to different polyphenol ligands is shown in
Figure 6-2B. The complexation with the ligand also affects the RMSF compared to the apo form
of the aggregate (see Figure 6-3). The RMSD of the ligands along the simulation time is shown
in Figure 6-2B curcumin shows largest RMSD (1-3.5 Å), the RMSD of myricetin was within 0.5
to 1.0 Å while the RMSD of exifone remains about 0.5 Å. Armstrong et al.242 have suggested the
planar structure of phenolic compounds could contribute to their effectiveness as inhibiting
aggregation by allowing them to intercalate between monomer layers. The hydrogen bond
170

analysis of curcumin (the most flexible ligand with few hydroxyl groups) indicates ligand
flexibility and number of strong hydrogen bond acceptor (the ketone carbonyl: two in curcumin
versus one in the other ligand) plays an important role in interaction of the ligand with the
peptides. A proper balance between molecular flexibility and number of strong hydrogen bond
donor/acceptor group could play a role in the designing of more potent polyphenols as
aggregation inhibitor.229

6.3.1

Average twist angle

Amyloid fibrils typically exhibit twisted β-sheets, as observed by electron microscopy
and solid state NMR. Since twisted β-sheets optimize the hydrogen bonds, side chain stacking,
and electrostatic interactions, it is commonly accepted that twisted sheets are more stable than
flat ones. While twisting, the β-sheets pairs remain to be complimentary via the steric
zippers.88The twisting in the SH4-ST7 aggregate of VQIVTK hexapeptide was evaluated by
considering pairs of dihedral angles, one per each sheet of the pair. Each dihedral angle is
calculated from the coordinates of the Cα(Gln2) and the Cα(Tyr6) atom of the second and the six
strand of the sheet. Twisting angles have been computed by using the five inner strands.79 As
shown in Table 6-2, for the VQIVYK oligomer with and without polyphenolic ligand, the
average twist angle of the oligomer with the ligand is larger than without the ligands. A large
twist angle between two adjacent strands may lead them to tear away from one another at a
relatively early stage of the simulation by disrupting the main chain and side-chain interactions
necessary for maintaining the bulk structure. The presence of the ligand leads is structural
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disruption exposing hydrophobic segments towards the polar solvent and the consequent
destabilization of the bulk organization.

6.3.2

Hydrogen bonding analysis

The ordered oligomer of VQIVYK is stabilized by an extensive network of inter-peptide
H-bonds. Hydrogen bonds contents of β-sheets were used previously to judge the structural
integrity and stability of the various β-sheet aggregates. We did an inter-peptide hydrogen
analysis and found the inter-peptide hydrogen bond content of VQIVYK oligomer with and
without polyphenols was stable across all simulations (see Figure 6-3A and Table 6-2).
Experimental and theoretical studies have suggested that the protein–polyphenol strong
association is driven by hydrophobic effects and stabilized by hydrogen-bonding interactions.

88

The polyphenol with hydroxyl groups, competitively interact with peptides through hydrogen
bonds. The analysis of the hydrogen bonds present between the oligomer aggregates and
polyphenols with time was obtained from a trajectory using ptraj module in AMBER11 and is
shown in Table 6-2 and Figure 6-3B. Polyphenols binds reversibly and relatively weakly with
peptide molecules. The pattern of H-bond formation between the polyphenols and VQIVYK
oligomer have been analyzed in detail by considering percentage of occupancy (percentage of
structures exhibiting the particular type of H-bond) and are shown in Table 6-3. We investigated
the hydrogen bonds between polyphenols and the adjacent residues. The hydrogen bond
occupancy (Table 6-4) shows the hydrogen bond with significantly high occupancy between the
ligand and the peptide occurs with tyrosine and lysine residues that are close to the ligand as
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shown in Table 6-3. In the case of curcumin the hydrogen bond acceptor with highest percentage
occupancy is from the carbonyl ketones (see Table 6-3).

6.3.3

Energetic Analysis of the binding

By the MM-PB(GB)SA analysis, the total free energy of binding could be separated into
electrostatic, van der Waals, and solute-solvent interactions, gaining, additional insights into the
physics of the VQIVYK oligomer-polyphenol association process. A single trajectory method
was employed such that the snapshot coordinates for both the bound and unbound states were
obtained from a single molecular dynamics simulation. For this analysis, 2500 equally spaced
snapshots were taken at intervals of 80 ps from the 20.0 ns production simulation of each MD
trajectory. The binding free energy and the energy components of the polyphenols and VQIVYK
oligomer complexes are summarized in Table 6-4. Both van der Waals and electrostatic
contributions are relevant to the interaction. According to Table 6-4, electrostatic (ΔEele) and van
der Waals (ΔEvdw) terms in the gas phase provide the major favorable contributions to the
polyphenols binding, whereas polar solvation energies (ΔGPB(GB)) impair the binding. The
nonpolar solvation energies (ΔGSA), which correspond to the burial of SASA upon binding,
barely contribute to the polyphenols binding. Further insight into the forces involved in
polyphenols and VQIVYK oligomer complex formation can be obtained by analyzing the
electrostatic and non-electrostatic contributions in Table 6-4. As demonstrated by numerous
studies, the electrostatic contribution generally disfavors the docking of ligand and receptor
molecules because the unfavorable change in the electrostatics of solvation is mostly, but not
fully, compensated by the favorable electrostatics within the resulting ligand-receptor complex243
173

Indeed, from Table 6-4, despite the favorable electrostatic energies in the gas phase (ΔEele), the
contributions of polar solvation energies to binding (ΔGPB(GB)) are unfavorable for the 3
complexes, and the sum of ΔEele and ΔGPB(GB), does not favor the binding. Table 6-4 also
suggests that the net result of non-electrostatic interaction which is the sum of ΔEvdw and ΔGSA,
is favorable for the formation of the complexes, and it this behavior has been proposed
previously as a general trend for noncovalent ligand-receptor associations.244 From the above
results, we can conclude that the binding free energies obtained for these complexes are driven
by more favorable nonpolar interactions rather than by electrostatic interactions. To provide
basic information on the most important residues in the binding of polyphenols to the VQIVYK
oligomer an inhibitor-residue free energy decomposition analysis was performed. The
calculation was done over the 2500 MD snapshots taken from the 20 ns simulation. According to
the free energy decomposition analysis (Figure 6-4), the binding between the VQIVYK and the
polyphenol is driven by selected “hot spots” that play a major role in VQIVYK −polyphenol
recognition. The most important residues are Ile9, Ile33, Ile57, Ile81, Ile129 and Tyr149.
Myricetin and exifone have been reported as tau aggregation inhibitors with a 1.2 μM and 3.2
μM IC50 respectively. The binding energy analysis is in qualitative agreement with the
experimental observation.231 The result form the simulation indicates that using the VQIVYK
oligomer structure as a pharmacophore for tau amyloid in combination with docking and MD
simulation could be effective in the virtual screening for lead discovery of small molecule
aggregation inhibitors. Recently Okimoto et al

83

used MD simulation of a protein-ligand

conformation obtained from molecular docking to estimate the binding free energies using MMPBSA method and for ligand ranking. The combined docking and MD simulation was found to
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improve by 1.6 to 4.0 time the enrichment performance compared to the used of docking method
alone. The binding of the polyphenols with the peptide disrupts the surface pattern thus increases
the solubility of small protofibrils. Such interaction remodels the tau oligomer into a
confirmation that is different from the peptide without the ligand (see Figure 6-5). The
remodeling of the peptide by the polyphenols will prevent the growth of the aggregate and will
lead to disaggregation of the tau.

6.4

Conclusions

The results from this work provide a valuable insight into the mechanism of the
interaction of polyphenols with the short segment of tau amyloid peptide. The study of the
VQIVYK oligomer pharmacophore of tau amyloid with polyphenols in an explicit solvent may
prove valuable in the future design and search of tau amyloid aggregation inhibitor.
1.

Polyphenol planarity with certain flexibility and presence of a strong hydrogen bond

acceptor (the ketone carbonyl) for formation of hydrogen bond with the residues of the peptide
closer to the ligand.
2.

The overall structure of the aggregates of the VQIVYK segment of tau peptide in

complex with the polyphenol ligands compared to the negative control aggregate model is
changing as is evidence by larger RMSD, RMSF and twist angles indicating the remodeling of
the aggregate by the polyphenol molecules.
3.

The binding free energy calculation showed electrostatic (ΔEele) and van der Waals

(ΔEvdw) terms in the gas phase provide the major favorable contributions to the polyphenols
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binding, whereas polar solvation energies (ΔGPB(GB)) impair the binding. The nonpolar solvation
energies (ΔGSA), which correspond to the burial of SASA upon binding, barely contribute to the
polyphenols binding. The free energy decomposition analysis of the binding between the
VQIVYK and the polyphenol is driven by selected “hot spots” that play a major role in
VQIVYK −polyphenol recognition. The most important residues are Ile9, Ile33, Ile57, Ile81,
Ile129, and Tyr149.
4.

The MM-PBSA (MM-GBSA) ranking of the polyphenols is in qualitative agreement with

their experimental binding ranking. Thus use of VQIVYK oligomer as pharmacophore for tau
amyloid in combination with docking and MD simulation could be an effective strategy in the
virtual screening for lead discovery of small molecule tau aggregation inhibitors.
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Table 6-1 Summary of simulated system of polyphenols with tau peptide segment VQIVYK and control oligomer
ID†

Content

1

VQIVYK oligomer with
a single of curcumin
VQIVYK oligomer with a
single of exofine
VQIVYK oligomer with a
single of myricetin
Control

2
3
4

Number of
water
molecules
5774

Systems

Box size

Simulation
length (ns)

Four sheets, seven strands (SH4-ST7)

77.2177.2177.21

20

5434

Four sheets, seven strands (SH4-ST7)

75.9975.99 75.99

20

5767

Four sheets, seven strands (SH4-ST7)

77.2477.2477.24

20

5956

Four sheets, seven strands (SH4-ST7)

77.9677.9677.96

20

†

The VQIVYK oligomer consists of a total four sheets with seven strands per sheets. The oligomer is organization with parallel sheet between strand per sheet and antiparallel between two sheets).
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Table 6-2 Summary of structural analysis VQIVYK oligomers with and without polyphenols
Models name
VQIVYK oligomer,
control
5.45(1.69)
2.59(1.95)
18.16(14.69)

VQIVYK oligomer
with curcumin
10.58(2.61)
4.70(1.93)
-8.70(3.85)

VQIVYK oligomer
with exofine
7.21(1.14)
2.66(0.98)
-17.45( 3.04)

VQIVYK oligomer with
myricetin
8.82(1.87)
3.51(1.22)
-4.50(2.75)

Sheet 2

-13.60(1.18)

-14.22 (1.46)

-14.41(1.32)

-15.37(3.83)

Sheet 3

-21.47(2.16)

5.16(9.96)

-11.33(3.13)

-12.83(3.03)

Sheet 4

-12.06(1.34)

-13.67(1.22)

-19.60(3.19)

-13.84(1.41)

Oligomer inter-peptide H-bonds

87.31(3.43)

85.22(3.32)

84.41(4.30)

81.42(5.06)

H-bond of ligand with oligomer

-

0.92(1.41)

0.51(0.86)

1.02(0.69)

Average interstrand
twist angle

Geometric parameters
<RMSD>
<RMSF>
Sheet 1

 Each number is averaged over 20 ns trajectory and the numbers in parenthesis are standard deviations.
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Table 6-3 Hydrogen bond occupancy between the polyphenols and the oligomer of VQIVYK segment of tau peptide
VQIVYK with curcumin
Hydrogen bond type

(%)

VQIVYK with exifone
Hydrogen bond type

(%)

VQIVYK with myricetin
Hydrogen bond type

(%)

donor
curcumin@O34

Acceptor
TYR131@HH

donor
71.8 exifone @O20

Acceptor
TYR 35@HH

donor
16.8 myricetin @O12

Acceptor
TYR35@HH

60.5

curcumin @O33

TYR131@HH

34.8 exifone @H30

TYR35@HH

14.6 TYR11@OH

myricetin @H30

46.4

curcumin @O33

TYR11@HH

26.2 exifone @O18

TYR35@HH

8.9 TYR131@OH

myricetin @H31

21.0

curcumin @OXT

curcumin @H36

15.8 exifone @O18

TYR11@HH

5.7 myricetin 169@O22

TYR11@HH

12.2

curcumin @O34

TYR155@HH

13.4 LYS54@OXT

LYS103@H1

2.9 LYS54@OXT

myricetin @H29

12.0
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Table 6-4 Summary of the MM-GB(PB)SA energy component analysis of the polyphenols with the VQIVYK oligomers

MMGBSA

VQIVYK oligomer with curcumin

Model name
VQIVYK oligomer with exifone

<∆Evdw>
<∆Eele>
<∆GPB>
<∆GSA>
<∆Gsolv>
<∆Gbinding>
MMPBSA
<∆Evdw>
<∆Eele>
<∆GPB>
<∆GSA>
<∆Gsolv>
<∆Gbinding>

-28.29 4.53
-18.589.09
36.719.06
-5.260.59
31.459.08
-15.423.26

-22.062.86
-8.718.38
29.147.96
-3.890.33
25.257.97
-5.51472.64

VQIVYK oligomer with
myricetin
-32.395.35
-15.628.31
38.848.66
-4.830.36
34.018.67
-14.024.33

-28.294.53
-18.589.09
35.67 9.67
-3.02 0.45
32.66 9.68
-14.213.88

-22.062.86
-8.718.38
28.35 8.46
-1.840.25
26.51 8.46
-4.254.59

-32.395.35
-15.628.31
41.03 10.85
-2.530.25
38.50 10.85
-9.514.25

*
Binding free energy components (kcal mol−1) and standard deviations calculated with MM-PBSA/ MM-GBSA for VQIVYK
oligomer (SH4-ST7): Average over 2500 snapshots of the trajectory. b Δ Evdw, non-bonded van der Waals energy; ΔEele, non-solvent
electrostatic potential energy; ΔGPB, electrostatic contributions to the solvation free energy calculated with Poisson-Boltzmann
equation; ∆GSA , ∆GSolv are nonpolar and total solvation energies; ΔG binding binding energy of the system. All energies are in kcal/mol:
ΔGbinding = ΔEvdw + ΔEele + ΔGsol; ΔGsol = ΔGPB + ΔGSA;
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Figure 6-1 Chemical structures of curcumin (A), exifone (B) and myricetin (C)
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Figure 6-2 RMDS as a function of the simulation time (A) Comparative RMSD analyses of
VQIVYK oligomer control and in complex with curcumin, exifone and myricetin and (B)
comparative RMSD of the inhibitor molecules with respect to the first snapshot
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Figure 6-3 Comparative RMSF analysis of the VQIVYK oligomer control and in complex with
curcumin, exifoneand myricetin
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Figure 6-4 Time evolution of the number of hydrogen bonds (A) Total inter peptide hydrogen
bonds (B) hydrogen bonds between the polyphenols and VQIVYK oligomer
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Figure 6-5 Decomposition of the free energy on a per residue basis for VQIVYK oligomer and
the polyphenol interaction
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Figure 6-6 The structure of the initial and final structure after 20 ns for the VQIVYK oligomer with and without polyphenols
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SUMMARY
This Thesis describes Molecular dynamic study aimed at understanding the effect steric
zipper mutation, polymorphic packing and polyphenols on the aggregation of amyloid peptides.
First we investigated the effect of various sizes and arrangements of oligomer seeds of
the wild-type and mutants of the three hexa-peptides fragments of Tau, Insulin and Aβ peptide
(VQIVYK, MVGGVV and LYQLEN) on their structural stability and dynamics. We found the
stability of the VQIVYK, MVGGVV and LYQLEN peptide oligomers increases with increasing
the number of β-strand. The Sh2-St4 model was found to stable enough that could possible act as
a stable seed in prompting amyloid fibril formation for all the three peptides. The binding energy
calculated by MM-PBSA method and the analysis of individual contributions to the binding
energy shows the hydrophobic interactions play an important role in stabilizing the structural
organizations between β-sheet layers in the oligomers. The result of the binding free energy
calculation also indicated that the wild type is the most stable structure compared to the mutants.
The single glycine substitution at the steric zipper interface disrupts the hydrophobic steric
zipper remarkably, indicating that the hydrophobic attraction is a major driving force for
stabilizing and aggregation of oligomers. Consequently, the substantial reduction in the van der
Waals intersheet interactions leads to destabilization of the oligomers. Overall, aggregation of
both wild type and mutant peptides is driven by nonpolar interaction. Thus, designing new
peptidomimetic inhibitors able to prevent the fibril formation based on the modification of steric
zipper motif of the oligomers, similar to the ones examined in this study may become a viable
therapeutic strategy.
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Next we investigated effects of sequence and packing arrangements on five pairs of short
segments of amyloid peptides with steric zipper polymorphism. The simulation revealed the
amyloid peptide rich in Q/N amino acid (GNNQQNY and NNQNTF) have a greater structural
stability than the short segments amyloid peptide lacking the Q/N amino acids (SSTNVG,
VQIVYK and MVGGVV). The Q/N residue rich short amyloid segments have larger hydrogen
bond contents and hydrogen bond occupancy. The overall increase of hydrogen bond in the Q/N
residue rich peptides with smaller RMSD, RMSF and greater stability suggests their stability is
mainly associated with an increase in side chain interaction and hydrogen bond contents. The
simulations of Q/NG mutants disrupted the steric zipper, leading to unstable oligomers. The
The MM-PBSA binding free energy method was applied to the study of the -sheet association.
The nonpolar component of free energy is more favorable, while the electrostatic solvation is
unfavorable for sheet to sheet interaction. This explains the acceleration of aggregation by
adding nonpolar co-solvents (methanol, triﬂuoroethanol, and hexaﬂuoroisopropanol).The
decomposition of the binding energy per residue showed the contribution of the N/Q side-chains
to the association of the 5 stranded double layer oligomers is larger than the other nonpolar and
small size amino acids at the interface, underlining the importance of Q/N amino acid in
stabilizing the short segment amyloid peptides in crystal free context.
Next we investigated the structural stability of the wild type and mutants of a single layer
models of insulin aimed at the design of short- and long-acting insulin analogs. We found the
stabilities of the single-layer insulin peptide oligomers increase as the number of strands
increases (dynamic cooperative effect). The binding energy calculated by the MM-GBSA
method shows that hydrophobic interactions play an important role in stabilizing the structural
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organization of the single-layer insulin. Per-residue decomposition shows that the key amino
acid residues for single layer insulin stability occur mainly in the β-sheet regions of chains A and
B. The binding energy decomposition also reveals due to the electrostatic repulsion between the
three negatively charged glutamates in adjacent insulin strands, electrostatic contribution to the
binding energy is unfavorable. The single glycine substitution at the steric zipper interface was
found to disrupts the hydrophobic contacts and reduces the van der Waals interactions in the
mutants, thus reducing the binding free energy. The binding free-energy calculation indicated
that the wild type is more structurally stable than most of the mutants. A comparison of the
binding free energy between the wild type and the chain-A mutants (Y14GA, L16GA and
N18GA) indicated that shape complementarity between neighboring strands plays a key role in
stabilizing the entire oligomeric structure. The secondary structure contents and the clustering
analysis of the trajectories of the single-layer insulin oligomers of various sizes showed that the
larger aggregates retain the fibril conformation but the smaller ones (SH1-ST1 and SH1-ST2)
lose this conformation. This observation could explain the observed shortening of the nucleation
lag phase of insulin aggregation with oligomer seeds. Based on the secondary structure contents
and the cluster analysis, we propose that SH1-ST4 is a critical nucleus for single-layer insulin
fibril oligomer growth. Our simulations of wildtype and single glycine mutants at the steric
zipper region can be targeted in the design of both short- and long-acting insulin analogs as well.
Aside from the design of such insulin analogs, the present study may prove useful in the rational
design of insulin aggregation inhibitors that can be used to stabilize insulin formulations, leading
to safer handling and more cost-effective storage of such formulations, especially in developing
countries.
195

Finally we investigated the interaction of polyphenols with short amyloid aggregates. The
results from this work provide a valuable insight into the mechanism of the interaction of
polyphenols with the short segment of tau amyloid peptide. The study of the VQIVYK oligomer
pharmacophore of tau amyloid with polyphenols in an explicit solvent may prove valuable in the
future design and search of tau amyloid aggregation inhibitor. Polyphenol planarity with certain
flexibility and presence of a strong hydrogen bond acceptor (the ketone carbonyl) for formation
of hydrogen bond with the residues of the peptide closer to the ligand. The overall structure of
the aggregates of the VQIVYK segment of tau peptide in complex with the polyphenol ligands
compared to the negative control aggregate model is changing as is evidence by larger RMSD,
RMSF and twist angles indicating the remodeling of the aggregate by the polyphenol molecules.
The binding free energy calculation showed electrostatic (ΔEele) and van der Waals (ΔEvdw)
terms in the gas phase provide the major favorable contributions to the polyphenols binding,
whereas polar solvation energies (ΔGPB(GB)) impair the binding. The nonpolar solvation
energies (ΔGSA), which correspond to the burial of SASA upon binding, barely contribute to the
polyphenols binding. The free energy decomposition analysis of the binding between the
VQIVYK and the polyphenol is driven by selected “hot spots” that play a major role in
VQIVYK −polyphenol recognition. The most important residues are Ile9, Ile33, Ile57, Ile81,
Ile129, and Tyr149. The MM-PBSA (MM-GBSA) ranking of the polyphenols is in qualitative
agreement with their experimental binding ranking. Thus use of VQIVYK oligomer as
pharmacophore for tau amyloid in combination with docking and MD simulation could be an
effective strategy in the virtual screening for lead discovery of small molecule tau aggregation
inhibitors.
196

In summary, we conclude MD simulation could be used in the atomic level understanding
of amyloid aggregation formation, could contributes to elucidating the driving force for the
thermodynamics of the aggregation, could contribute in the structure based designing of
aggregation inhibitors and in combination with docking and MM-PBSA binding free energy
calculation could be useful in the virtual screening of inhibitors.
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